

PCTWORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : A61K 49/00, 51/04	A1	(11) International Publication Number: WO 95/32741 (43) International Publication Date: 7 December 1995 (07.12.95)
(21) International Application Number: PCT/EP95/01958 (22) International Filing Date: 23 May 1995 (23.05.95) (30) Priority Data: MI94A001074 26 May 1994 (26.05.94) IT (71) Applicant (for all designated States except AU CA GB IE US): BRACCO S.P.A. [IT/IT]; Via E. Folli, 50, I-20134 Milano (IT). (71) Applicant (for AU CA GB IE only): DIBRA S.P.A. [IT/IT]; Piazza Velasca, 5, I-20122 Milano (IT). (72) Inventors; and (75) Inventors/Applicants (for US only): ANELLI, Pier, Lucio [IT/IT]; Via E. Folli, 50, I-20134 Milano (IT). DE HAËN, Christoph [CH/IT]; Via E. Folli, 50, I-20134 Milano (IT). LATTUADA, Luciano [IT/IT]; Via E. Folli, 50, I-20134 Milano (IT). MOROSINI, Pierfrancesco [IT/IT]; Via E. Folli, 50, I-20134 Milano (IT). UGGERI, Fulvio [IT/IT]; Via E. Folli, 50, I-20134 Milano (IT). (74) Agents: MINOJA, Fabrizio; Studio Consulenza Brevettuale, Via Rossini, 8, I-20122 Milano (IT) et al.		(81) Designated States: AM, AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IS, JP, KG, KP, KR, KZ, LK, LR, LT, LU, LV, MD, MG, MN, MX, NO, NZ, PL, PT, RO, RU, SE, SG, SI, SK, TJ, TM, TT, UA, US, UZ, VN, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG), ARIPO patent (KE, MW, SD, SZ, UG). Published <i>With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>
(54) Title: BILE ACID CONJUGATES, DERIVATIVES THEREOF WITH METAL COMPLEXES AND RELATED USES (57) Abstract The invention relates to novel paramagnetic metal ion chelates and their use as contrast agents in the diagnostic technique known as "magnetic resonance imaging" (M.R.I.).		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	GB	United Kingdom	MR	Mauritania
AU	Australia	GE	Georgia	MW	Malawi
BB	Barbados	GN	Guinea	NE	Niger
BE	Belgium	GR	Greece	NL	Netherlands
BF	Burkina Faso	HU	Hungary	NO	Norway
BG	Bulgaria	IE	Ireland	NZ	New Zealand
BJ	Benin	IT	Italy	PL	Poland
BR	Brazil	JP	Japan	PT	Portugal
BY	Belarus	KE	Kenya	RO	Romania
CA	Canada	KG	Kyrgyzstan	RU	Russian Federation
CF	Central African Republic	KP	Democratic People's Republic of Korea	SD	Sudan
CG	Congo	KR	Republic of Korea	SE	Sweden
CH	Switzerland	KZ	Kazakhstan	SI	Slovenia
CI	Côte d'Ivoire	LI	Liechtenstein	SK	Slovakia
CM	Cameroon	LK	Sri Lanka	SN	Senegal
CN	China	LU	Luxembourg	TD	Chad
CS	Czechoslovakia	LV	Latvia	TG	Togo
CZ	Czech Republic	MC	Monaco	TJ	Tajikistan
DE	Germany	MD	Republic of Moldova	TT	Trinidad and Tobago
DK	Denmark	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	US	United States of America
FI	Finland	MN	Mongolia	UZ	Uzbekistan
FR	France			VN	Viet Nam
GA	Gabon				

BILE ACID CONJUGATES, DERIVATIVES THEREOF WITH METAL
COMPLEXES AND RELATED USES

The present invention relates to novel paramagnetic metal ion chelates and their use as contrast agents in the diagnostic technique known as "magnetic resonance imaging" (M.R.I.). In particular,
5 the present invention relates to bile acid conjugates with molecules endowed with a chelating capacity, as well as their complex chelates with paramagnetic metal ions and/or their salts and the use of these complexes as contrast agents for M.R.I.

10 Complexes formed of chelating agents and suitable specific metals are already used as contrastographic agents in the following diagnostic techniques: X ray imaging, nuclear magnetic resonance imaging (M.R.I.) and scintigraphy.

15 In particular, medical diagnosis using "magnetic resonance imaging" (M.R.I.), recognized as a powerful diagnostic agent in clinical practice (Stark, D.D., Bradley, W.G., Jr., Eds. "Magnetic Resonance Imaging" The C.V. Mosby Company, St. Louis, Missouri (USA),
20 1988), employs, above all, paramagnetic pharmaceutical compositions, preferably containing complex chelates of bi-trivalent paramagnetic metal ions with aminopolycarboxylic acids and/or their derivatives or analogues.

25 Some of them are at present in clinical use as contrast agents for M.R.I. (Gd-DTPA, N-methylglucamine salt of the gadolinium complex with diethylenetriamino-pentacetic acid, MAGNEVIST^R, Schering; Gd-DOTA, N-

methylglucamine salt of the gadolinium/1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid complex, DOTAREM^R Guerbet).

In order to illustrate the state of the art in this field, here follows a list, incomplete, though indicative, of significant patent documents: EP 71564 (Schering), US 4639365 (Sherry), US-A-4615879 (Runge), DE-A-3401052 (Schering), EP 130934 (Schering), EP 65728 (Nycomed), EP 230893 (Bracco), US-A-4826673 (Mallinckrodt), US-A-4639365 (Sherry), EP 299795 (Nycomed), EP 258616 (Salutar), WO 8905802 (Bracco).

The contrast agents listed above and on the market are designed for a wholly general use. In fact, after administration the MRI contrast agent is distributed in the extracellular spaces in different parts of the body prior to being excreted. In this sense they behave in a similar manner to iodine compounds used in X ray medical diagnosis.

Today, more than ever, the medical profession is in need of contrast agents that are aimed at specific organs, a need which is not adequately met by the products on the market at present. Especially, there is a need for contrast agents for the liver, an organ which is particularly prone to tumoral metastasis and which are almost always carcinomatose metastasis. Agents of this type should be able to provide the following results:

- a) to clearly and selectively show the healthy tissue of the liver, thereby permitting the pin-pointing of small lesions such as metastasis (focal liver disease);

3

- b) an indication of hepatic function, whereby a disease as widespread as cirrhosis of the liver may be clearly exposed;
- c) a high resolution visualization of the bile ducts and of the gall bladder.

Primary hepatic carcinoma (HCC) is a pathology which has become increasingly and rapidly widespread in the last twenty years, both in the Western World and in Japan (Okuda K., Hepatology, 15, 948, 1992). As a result of this, the need for a fast and efficient method of diagnosis for the detection of HCC emerges; to this purpose, Magnetic Resonance takes on a leading rôle, the proviso being the availability of a contrast agent which allows for the differentiation between the healthy hepatocytes and those which are affected.

Today, only one product (AMI-HS of Advanced Magnetics, Reimer, P.; Weissleder, R. et al.; Radiology 177, 729, 1990, patent application WO-9001295) seems to possess the necessary prerequisites for the diagnosis of HCC. One is dealing with "ultra-small" particles of iron oxide (average diameter: 12nm) coated with arabinogalactose which have a particular affinity with the asialoglycoprotein receptors present on the surface of the hepatocytes. However, the use of these particles brings about various side effects, especially with regard to the circulatory system. The identification of an ideal hepatospecific contrast agent is, therefore, still far off.

Among the M.R.I. contrast agents under development, both the compound known as Gd-BOPTA (BRACCO, EP 230893), and the Schering product Gd-EOB-

DTPA (EP-A-405704) turned out to be particularly suitable for the visualization of hepatic tissue, due to their characteristics of also being excreted via the bile tract.

5 The transport of both endogene and xenobiotic substances by means of the hepatocytes and the biliary excretion mechanisms have been amply discussed in the literature, only a few basic concepts of which shall be recalled as follows (see, for example, Meier, P.J. in
10 "Biliary Excretion of Drugs and Other Chemicals", Siegers, C.-P. and Watkins III J.B. Eds. Gustav Fischer Verlag, Stuttgart, 1991).

 The passage of a molecule in bile from blood through the Disse space takes place in numerous stages
15 that may be schematically summarized as follows:

- the molecule enters the hepatocyte through the sinusoid membrane following a mechanism that may or may not be specific (mediated by a carrier or a receptor).
- inside the hepatocyte the molecule may: 1) be
20 carried unaltered and linked to an intracellular protein or inside a vesicle, 2) undergo a conjugation reaction with an enzyme and be excreted in the bile as a conjugate, 3) be enzymatically degraded inside the
25 - the molecule leaves the hepatocyte through the bile canaliculus membrane via a mechanism mediated by a carrier or through an exocytosis mechanism (if the molecule is carried inside the vesicle).

 If the aim is to synthesize a hepatotropic
30 contrast agent which enters the hepatocytes, the mechanisms that turn out to be the most interesting are

those which are mediated by a receptor or a carrier. Up to now, the following carriers have been identified and partially characterized on the membrane sinusoid:

- bile acid carriers
- 5 - a bilirubin carrier
- a fatty acid carrier
- a carrier for organic cations

The first two types of carrier have been studied more in depth and the knowledge with regard to them is
10 far more advanced.

The HCC cellular lines studied to date turn out to be made up of hepatocytes which possess the bilirubin carriers. As both Gd-BOPTA and Gd-EOB-DTPA seem to penetrate the interior of the hepatocytes taking
15 advantage of said carrier, both products may not be of any help in the diagnosis of HCC, insomuch that they are not capable of differentiating between healthy and affected hepatocytes.

It has been shown that in some human HCC lines the hepatocytes are free from tauroalcoholic acid carriers (von Dippe, P; Levy, D.; J. Biol. Chem. 265, 5942, 1990 and cited references). It appears, therefore, that research for a contrast agent that utilizes this carrier for penetrating hepatocytes is of great
20 interest.

Patent Application (EP-A-279307, Abbott) claims polyaminocarboxylic chelant conjugates, able to complex metal ions, with different substrates, among which are the bile acids. The only illustrative complex in the
25 case of the Patent Application is a ¹¹¹In complex of a conjugate in which a functionalized derivative of EDTA

is covalently linked, through an amide link, to the carboxylic function of cholic acid. The possibility of chelating paramagnetic metal ions for the use in MRI is not referred to in any way.

5 Another Patent Application (EP-A-417725, Hoechst) generally claims products in which a bile acid is conjugated with pharmacologically active residues such as peptids, antibiotics, antivirals, renin inhibitors and medicaments for the treatment of diabetes.
10 Recently, the results of the use of bile acid conjugates with chlorambucil, an antitumoral agent with cytotoxic action (Kramer, W. et al.; J. Biol. Chem, 267, 18598, 1992).

The present invention relates to novel compounds
15 resulting from the conjugation of a bile acid with a chelating agent and capable of chelating the ions of bi-trivalent metals.

The present invention also relates to the complex
chelates of said molecules with the ions of bi-
20 trivalent metals, as well as the salts of said chelates.

Said compounds turned out to be excellent MRI contrast agents, particularly for the "imaging" of the hepatobiliary system.

25 The present invention relates to the compounds of general formula (I):



wherein

A is the residue of a bile acid, wherein by bile
30 acid the group of the bile acids obtainable by bioconversion from cholesterol is meant,

7

particularly the acids: cholic, deoxycholic, chenodeoxycholic, ursodeoxycholic, lithocholic, and the derivatives thereof, including those with taurine and glycine;

- 5 L is a linker between one of the C-3, C-7, C-12 or C-24 positions of the residue of the bile acid and B, corresponding to a group of formula (II)




10

in which

m is an integer varying from 1 to 10, wherein for values above 1,

Y can have different meanings,

- 15 Y corresponds to the following succession of groups,



- 20 n, 1 and q can be 0 or 1,

p can vary from 0 to 10,

X is an O atom, a S atom, or a -NR group,

in which

R is a H atom, or a (C₁-C₅) alkyl group,

- 25 K is benzene ring, substituted or not, or a -CHR₁ group,

wherein

R₁ is an hydrogen atom, or a -COOH group, or a -SO₃H group,

- 30 Z is an O atom or a S atom, or one of the -CO- or -CS- groups,

B is the residue of a chelating agent of bivalent metal ions having an atomic number varying from 20 to 31, 39, 42, 43, 44, 49, or from 57 to 83, wherein said residue can in its turn be conjugated or not, by a second chain L of formula (II), to another residue A as defined above, with the proviso that at least one from l, n, q, p is different from 0 and, when X and Z are both O or S atoms, q or n is equal to 1.




10 An object of the invention also are the complex chelates of said compounds of formula (I) with the bivalent ions of metal elements having an atomic number varying from 20 to 31, 39, 42, 43, 44, 49, or from 57 to 83, as well as the salts thereof with 15 physiologically compatible organic bases selected from primary, secondary, tertiary amines or basic amino acids, or with inorganic bases the cations of which are sodium, potassium, magnesium, calcium or mixtures thereof, or with anions of physiologically acceptable 20 organic acids, for example selected from acetate, succinate, citrate, fumarate, maleate, oxalate, or with anions of inorganic acids such as the ions of the halohydric acids, i.e. chlorides, bromides, iodides.

The compounds of the present invention can 25 optionally be conjugated chemically to suitable macromolecules or inglobated into suitable carriers.


Object of the invention are also the preparation of the products of general formula (I) and of the complex salts thereof, the uses thereof and the related 30 pharmaceutical compositions for diagnostic use.

Particularly preferred compounds of the present

invention are those in which the spacing chains L have the following general formulae (III), (IV), (V), (VI)




10




10 Moreover, particularly preferred are moreover the structures in which A is a residue deriving from the following bile acids or from their derivatives with taurine and glycine:

Bile acids


15




Cholic acid



Chenodeoxycholic acid




Deoxycholic acid



Ursodeoxycholic acid

11



5

Lithocholic acid

The bond between A and L is obtained making use either of the acidic function at the 24- position, or by functionalizing the hydroxy groups at the 3-, 7-, 12- positions, independently from the stereochemistry of the final products.

B is preferably the residue of a polyaminopolycarboxylic acidic linker and derivatives thereof, particularly diethylenetriamino pentaacetic acid (DTPA), 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA), 1,4,7,10-tetraazacyclododecane-1,4,7-triacetic acid (DO3A), [10-(2-hydroxypropyl)-1,4,7,10-tetraazacyclododecane-1,4,7-triacetic acid (HPDO3A), 4-carboxy-5,8,11-tris(carboxymethyl)-1-phenyl-2-oxa-5,8,11-triazatridecan-13-oic acid (BOPTA), N-[2-[bis(carboxymethyl)amino]-3-(4-ethoxyphenyl)propyl]-N-[2-[bis(carboxymethyl)amino]ethylglycine (EOB-DTPA), N,N-bis[2-[(carboxymethyl)[(methylcarbamoyl)methyl]amino]ethyl]glycine (DTPA-BMA), 2-methyl-1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (MCTA), (α,α',α'',α''')-tetramethyl-1,4,7,10-tetraazacyclododecane-1,4,7,10-tetracetic acid (DOTMA); or B is the residue of a polyaminophosphate acidic linker or of the derivatives thereof, particularly N,N'-bis-(pyridoxal-5-phosphate)ethylenediamino-N,N'-diacetic acid (DPDP) and ethylenedinitrilotetrakis(methylphosphonic) acid

12

(EDTP); or B is the residue of a polyaminophosphonic acid linker and the derivatives thereof, or polyaminophosphinic acid and the derivatives thereof, particularly 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetrakis[methylen(methylphosphonic)] acid and 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetrakis[methylen(methylphosphinic)] acid; or B is the residue of macrocyclic chelating agents such as texaphyrins, porphyrins and phthalocyanines.

The link to the spacing chain can be obtained by means of the acidic groups of the linker or by a suitable reactive group present in the starting linker, for example an amino group, or a functional group present on a phenyl, etc.

Particularly preferred reactive groups are selected from the group consisting of $-\text{NH}_2$, $-\text{NCS}$, $-\text{NHCSNHNH}_2$, $-\text{NHCSNH}(\text{CH}_2)_2\text{NH}_2$, $-\text{NCO}$, $-\text{NHNH}_2$, $-\text{NHCONHNH}_2$, $-\text{CHO}$.

Particularly preferred are the structures in which A is a residue of cholic acid, B is a residue of the linker BOPTA, of DTPA or of DOTA.

Metal ions suitable to form complex salts with the chelating agents of general formula (I) are mainly the bivalent or trivalent ions of the elements having atomic numbers varying from 20 to 31, 39, 42, 43, 44, 49, or from 57 to 83; particularly preferred are $\text{Fe}(2+)$, $\text{Fe}(3+)$, $\text{Cu}(2+)$, $\text{Cr}(3+)$, $\text{Gd}(3+)$, $\text{Eu}(3+)$, $\text{Dy}(3+)$, $\text{La}(3+)$, $\text{Yb}(3+)$ or $\text{Mn}(2+)$ or also radioisotopes such as ^{51}Cr , ^{67}Ga , ^{68}Ga , ^{111}In , $^{99\text{m}}\text{Tc}$, ^{140}La , ^{175}Yb , ^{153}Sm , ^{166}Ho , ^{90}Y , ^{149}Pm , ^{177}Lu , ^{47}Sc , ^{142}Pr , ^{159}Gd , ^{212}Bi .

The compounds of general formula (I) can be

prepared with synthesis methods conventionally known in industrial technology. Particularly, MRI contrast agents conjugated with bile acids can be prepared by means of a convergent synthesis which comprises:

- 5 1) synthesis of a functionalized ligand i.e. of a ligand capable of coordinating one paramagnetic metal ion and at the same time of bind stably to the bile acid by means of a suitable functional group;
- 10 2) synthesis of a functionalized bile acid;
- 3) coupling reaction between two different syntons;
- 4) cleavage of any protective groups;
- 5) complexation of the paramagnetic metal ion.

In the following Scheme 1, some of the functional groups most easily obtainable respectively on cholic acid and on the ligand, as well as the mutual possibilities to react to give stable bonds are reported by way of example.


Scheme 1

20

Functional groups

Cholic acid

25 Ligand



As it can be observed, the conjugation of the two syntons is carried out through three different known binding methods, widely used in synthesis (see Brinkley, M., Bioconjugate Chem. 1992, 3, 2), which involve formation of an amide (path a), of a thiourea

14





(path b) or, through reduction of the intermediate imine, of an amine (path c).

The functional groups of the two syntons of Scheme 1 are moreover liable to further modifications before the binding reaction, for example by reaction with

An example of ligands corresponding to point 1) described above is represented by the molecules in Scheme 2.

10

Scheme 2



By way of non-limiting example, the synthesis of ligands C and D, the latter being the glycine derivative (Scheme 3), can be cited herein.

The synthesis of t-butyl 2-bromo-3-[(4-nitrophenyl)methoxy]propionate was performed according to the procedure described by P. L. Rings et al., Synth. Commun., 23, 2639, 1993. In a similar way, starting from t-butyl 2-bromo-4-[(4-nitrophenyl)]butanoate (prepared according to the procedure described in Kruper W.J.; Rudolf P.R.; Langhoff C.A. J. Org. Chem., 58, 3869, 1993), a ligand which involves no benzyloxy groups can be prepared.


In Scheme 3 the t-butyl esters are shown, but they can easily be substituted by other alkyl groups.

The synthesis continues with the condensation of the α -bromopropionic intermediate with diethylenetriamine and the subsequent carboxymethylation with t-butyl α -bromoacetate under the usual conditions known in literature.

The reduction of the nitro group is performed by means of hydrogen using 10% Pd/C as the catalyst. At this point, the key synton is available for binding through the amino group present on an aromatic ring of the ligand with the acidic groups of the bile acids or with derivatives thereof in which carboxylic groups are present.

16

Scheme 3



An example of functionalization of the steroid can be represented by the synthesis of cholic acid 3 β -amino derivative according to Scheme 4, using in an original way the Mitsunobu reaction (Review, Synthesis, 1, 1981) which allows the selective transformation of the 3 α hydroxyl group into the corresponding 3 β azido group.

30


17

Scheme 4

5

10

15




Intermediate G can be used as such or it can easily be changed into other intermediates as much interesting, as evidenced in Scheme 5.

Scheme 5

20

25

30



18

An example of binding reaction between the components A and B of general formula (I) of the compounds of the present invention, is the formation of the amido bond between the steroid carboxylic group at the 24- position and the amino group present in the
5 ligand, for example C and D of Scheme 2.

The reaction is preferably activated by the addition of diethoxyphosphoryl cyanide (DEPC), according to the procedure described for the peptide
10 synthesis (Shioiri, T et al., Tetrahedron, 32, 2211, 1976). The reaction with DEPC takes place preferably in a dipolar aprotic solvent, such as dimethylformamide (DMF) or dimethylacetamide (DMA) or in a mixture thereof, at a temperature varying from -5°C to 40°C,
15 preferably from 0°C to 25°C.

A further example of binding reaction makes use of the formation of a Schiff base between the ligands of type E and F and a suitable steroid derivative, for example the derivative J obtained from 3 β -aminocholic
20 derivative according to Scheme 5.

The aldehyde group of the ligand reacts with the amino group present on the steroid and subsequently the amino derivative is reduced with NaBH₃CN, according to a well-known procedure of the literature (C.F. Lane,
25 Synthesis, 135, 1975).

The choice of diversifying the ester groups present in both components of the binding reaction, allows for the modulation of the hydrolysis thereof in different synthesis steps.

30 The conversion of the ester groups of t-butyl type into acidic groups takes place in acid solution. The

resulting solution is adjusted to controlled pH thus allowing the simultaneous formation of the desired complex by addition of the stoichiometric amount of metal, in the form of oxide or salt.

5 The hydrolysis reaction of the ester groups of methyl type takes place preferably in the presence of a suitable organic or inorganic base such as sodium hydroxide, potassium hydroxide, potassium carbonate or, for example, lithium hydroxide at a pH value varying
10 from 8 to 12, preferably between 0°C and 100°C, more preferably between 0°C and 50°C.

 The possible conjugation with the amino acids taurine and glycine takes place according to the procedure described in Tserng, K-Y.; Hachey, D.L.;
15 Klein, P.D. J. Lipid Res. 1977, 18, 404.

 Finally, the formation of the metal complex salt is preferably carried out in water or in a suitable water-alcohol mixture, whereas the temperature can vary from 25°C to 100°C, preferably from 40°C to 80°C.

20 The choice of the metal ion and of any neutralizing ions is strictly related to the use of the complex to be prepared.

 The novel compounds of the present invention proved to have a good tolerability; moreover their
25 water solubility and the low osmolality of the solutions are another important feature making them particularly suited for the use in nuclear magnetic resonance.

 The in vitro relaxivity data evidenced for the
30 compounds of the present invention turned out to be quite good. By way of non-limiting example, the r_1 and

20

r_2 values found for two of the preferred compounds of the invention, i.e. the 4-carboxy-5,8,11-tris(carboxymethyl)-1-[4-[[[(3 α ,5 β ,7 α ,12 α)-3,7,12-trihydroxy-24-oxocholan-24-yl]amino]acetyl]amino]phenyl]-2-oxa-5,8,11-triazatridecan-13-oic acid gadolinium complex salified with 1-deoxy-1-(methylamino)-D-glucitol (1:2), and [[10-[2-Oxo-2-[[3-[[2-[[[(3 α ,5 β ,7 α ,12 α)-3,7,12-trihydroxy-24-oxocholan-24-yl]amino]ethyl]amino]propyl]-amino]ethyl]-1,4,7,10-tetraazacyclododecan-1,4,7-triacetate(3⁻)]gadolate(0)] hydrogen compound with HCl (1:1), are reported in EXAMPLE 19, compared with the data available for paramagnetic compounds marketed under the trade marks MAGNEVIST^R (Schering) and DOTAREM^R (Guerbet), or with the data related to Gd-BOPTA and to the Gd³⁺ ion as such.

Both soluble and less soluble compounds are suited for the oral or enteral administrations and, therefore, particularly for the gastrointestinal tract imaging.

For the parenteral administration, they are preferably formulated as sterile aqueous solutions or suspensions, whose pH can range, for example, from 6.0 to 8.5.

Said aqueous solutions or suspensions can be administered in concentrations varying from 0.002 to 1.0 Mol.

Said formulations can be freeze-dried and provided as such for the extemporary use. For the gastrointestinal use or for the injection in body cavities, said agents can be formulated as solutions or suspensions containing appropriate additives suitable, for example, to control viscosity.

For the oral administration, they can be formulated according to preparation methods conventionally used in pharmaceutical technique, possibly also as coated formulations to obtain an additional protection against the stomach acidic pH, thus preventing the chelated metal ion from release, which takes place particularly at the pH values typical of gastric juices.

Other excipients, such as sweeteners and/or flavouring agents, can also be added, according to known techniques of pharmaceutical formulations.

As far as the diagnostical use of the chelates of the present invention is concerned, they can also be used as both contrast media and therapeutical agents, in nuclear medicine.

In this case, however, the metal ion which is chelated is a radioisotope, for example ^{51}Cr , ^{67}Ga , ^{68}Ga , ^{111}In , $^{99\text{m}}\text{Tc}$, ^{140}La , ^{175}Yb , ^{153}Sm , ^{166}Ho , ^{90}Y , ^{149}Pm , ^{177}Lu , ^{47}Sc , ^{142}Pr , ^{159}Gd and ^{212}Bi .

Preferred inorganic base cations possibly suitable to salify the complex chelates of the present invention comprise particularly the alkali or alkaline-earth metal ions such as potassium, sodium, calcium, magnesium, and mixtures thereof.

Preferred organic base cations suitable for the above mentioned purpose comprise, inter alia, those of primary, secondary and tertiary amine, such as ethanolamine, diethanolamine, morpholine, glucamine, N-methylglucamine, N,N-dimethylglucamine.

Preferred inorganic acid anions possibly suitable to salify the complex chelates of the present invention

comprise, particularly, the halohydric acid ions, such as chlorides, bromides, iodides or other ions such as sulfate.


Preferred organic acid anions for the above mentioned purpose comprise those of acids conventionally used in pharmaceutical techniques for the salification of alkali substances, such as acetate, succinate, citrate, fumarate, maleate.

Preferred amino acid cations and anions comprise, for example, those of taurine, glycine, lysine, arginine or ornithine or of the aspartic and glutamic acids.

The complex chelates conjugated with the bile acids, object of the present invention, can also be inglobated into liposomes or be components of their chemical structure and be used as mono- or multi-lamellar vescicles.

A non-limiting list of preferred compounds of the invention (described in the experimental part) is reported in the following to illustrate further the present invention.

COMPOUND 1 (EXAMPLE 1)




[[[4-carboxy-5,8,11-tris(carboxymethyl)-1-[4-
[[[(3a,5β,7α,12α)-3,7,12-trihydroxy-24-oxocholan-24-

23

amino]acetyl]amino]phenyl]-2-oxa-5,8,11-triazatridecan-13-oic acid


COMPOUND 2 (EXAMPLE 2)



[[4-carboxy-5,8,11-tris(carboxymethyl)-1-[4-
[[[(3 α ,5 β ,7 α ,12 α)-3,7,12-trihydroxy-24-oxocholan-24-
yl]amino]phenyl]-2-oxa-5,8,11-triazatridecan-13-oic
acid

15


COMPOUND 3 (EXAMPLE 3)



[[3,6,9-tris(carboxymethyl)-10-(phenylmethoxy)methyl-
11-oxo-14-[[[3 α ,5 β ,7 α ,12 α)-3,7,12-trihydroxy-24-oxocho-
lan-24-yl]amino]-3,6,9,12-tetraazatetradecanoic acid

25

COMPOUND 4 (EXAMPLE 4)




24

[[10-[2-oxo-2-[[3-[[2-[[[(3 α ,5 β ,7 α ,12 α)-3,7,12-trihydroxy-24-oxocholan-24-yl]amino]ethyl]amino]propyl]-amino]ethyl]-1,4,7,10-tetraazacyclododecan-1,4,7-triacetic acid

5

COMPOUND 5 (EXAMPLE 5)

10




[[[(3 β ,5 β ,7 α ,12 α)-3-[[13-carboxy-6,9,12-tris(carboxymethyl)-1,4-dioxo-5-[(phenylmethoxy)methyl]-3,6,9,12-tetraazatridecyl]amino]-7,12-dihydroxy-cholan-24-oic acid

15

COMPOUND 6 (EXAMPLE 6)

20




[[[(3 β ,5 β ,7 α ,12 α)-3-[[17-carboxy-10,13,16-tris(carboxymethyl)-8-oxo-9-[(phenylmethoxy)methyl]-3,7,10,13,16-pentaazaheptadecyl]oxy]-7,12-dihydroxy-cholan-24-oic acid

25

COMPOUND 7 (EXAMPLE 7)

30




25

[[[(3 β ,5 β ,7 α ,12 α)-7,12-dihydroxy-3-[2-[[[4-[4,12-bis(carboxy)-5,8,11-tris(carboxymethyl)-2-oxa-5,8,11-triazadodecyl]phenyl]amino]thioxomethyl]amino]ethoxy]-cholan-24-oic acid

5

COMPOUND 8 (EXAMPLE 4)




10

(3 β ,5 β ,7 α ,12 α)-7,12-dihydroxy-3-[[[3-[[[4,7,10-tris(carboxymethyl)-1,4,7,10-tetraazacyclodec-1-yl]acetyl]-amino]propyl]amino]acetyl]amino]-cholan-24-oic acid

15

COMPOUND 9 (EXAMPLE 8)




20

[[3,6,9-tris(carboxymethyl)-10-[(phenylmethoxy)methyl]-11-oxo-17-[[[(3 α ,5 β ,7 α ,12 α)-3,7,12-trihydroxy-24-oxocholan-24-yl]amino]-3,6,9,12-tetraazaoctadecanedioic acid

25

COMPOUND 10 (EXAMPLE 9)




30

26

[[(3 β ,5 β ,7 α ,12 α)-3-[[13-carboxy-6,9,12-tris(carboxymethyl)-1,4-dioxo-3,6,9,12-tetraazatridecyl]amino]-7,12-dihydroxy-cholan-24-oic acid


COMPOUND 11 (EXAMPLE 10)



15

[[(3 β ,5 β ,7 α ,12 α)-(3' β ,5' β ,7' α ,12' α)-3,3'-[[6,9,12-tris(carboxymethyl)-1,4,14,17-tetraoxo-3,6,9,12,15-pentazaheptadecan-1,17-diyl]bisimino]bis[7,12-dihydroxycholan-24-oic acid

COMPOUND 12 (EXAMPLE 11)




25

[[[3 β (S),5 β ,7 α ,12 α]-7,12-dihydroxy-3-[[4-[[[5-[bis[2-bis(carboxymethyl)amino]ethyl]amino]-5-carboxypentyl]-amino]thioxomethyl]amino]benzoyl]amino]-cholan-24-oic acid

30


27

COMPOUND 13 (EXAMPLE 12)




10 [[[(3 β (S),5 β ,7 α ,12 α)-7,12-dihydroxy-3-[[4-[[5-[bis[2-
[bis(carboxymethyl)amino]ethyl]amino]-5-carboxypen-
tyl]amino]-1,4-dioxobutyl]amino]-cholan-24-oic acid

COMPOUND 14 (EXAMPLE 13)



20 [[[(3 β ,5 β ,7 α ,12 α)-7,12-dihydroxy-3-[[4-[[2-[[4-[4,12-
bis(carboxy)-5,8,11-tris(carboxymethyl)-2-oxa-5,8,11-
triazadodecyl]phenyl]amino]-2-oxoethyl]amino]-1,4-dio-
xobutyl]amino]-cholan-24-oic acid;

COMPOUND 15 (EXAMPLE 5)




28

3,6,9-tris(carboxymethyl)-14-[[[(3 β ,5 β ,7 α ,12 α)-7,12-dihydroxy-24-oxo-24-[(2-sulfoethyl)amino]-cholan-3-yl]amino]-11,14-dioxo-10-(phenylmethoxy)methyl-3,6,9,12-tetraazatetradecanoic acid

5

COMPOUND 16 (EXAMPLE 5)

10




15

N-[(3 β ,5 β ,7 α ,12 α)-3-[[[13-carboxy-6,9,12-tris(carboxymethyl)-1,4-dioxo-5-[(phenylmethoxy)methyl]-3,6,9,12-tetraazatridecyl]amino]-7,12-dihydroxy-24-oxocholan-24-yl]glycine

COMPOUND 17 (EXAMPLE 5)

20



25


(3 β ,5 β ,7 α)-3-[[[13-carboxy-6,9,12-tris(carboxymethyl)-1,4-dioxo-5-[(phenylmethoxy)methyl]-3,6,9,12-tetraazatridecyl]amino]-7-hydroxy-cholan-24-oic acid

30

29

COMPOUND 18 (EXAMPLE 5)


5



(3 β ,5 β ,12 α)-3-[[13-carboxy-6,9,12-tris(carboxymethyl)-
1,4-dioxo-5-[(phenylmethoxy)methyl]-3,6,9,12-tetraaza-
tridecylamino]-12-hydroxy-cholan-24-oic acid

COMPOUND 19 (EXAMPLE 5)


15



(3 β ,5 β)-3-[[13-carboxy-6,9,12-tris(carboxymethyl)-1,4-
dioxo-5-[(phenylmethoxy)methyl]-3,6,9,12-tetraazatri-
decylamino]-cholan-24-oic acid

COMPOUND 20 (EXAMPLE 5)

25




30

30

(3 β ,5 β ,7 α ,12 α)-3-[[17-carboxy-10,13,16-tris(carboxymethyl)-1,8-dioxo-9-[(phenylmethoxy)methyl]-7,10,13,16-tetraazaheptadecyl]amino]-7,12-dihydroxy-cholan-24-oic acid

5

COMPOUND 21 (EXAMPLE 4)




10

(3 β ,5 β ,7 α ,12 α)-7,12-dihydroxy-3-[[3-[[[4,7,10-tris(carboxymethyl)-1,4,7,10-tetraazacyclododec-1-yl]acetyl]-amino]propyl]amino]-cholan-24-oic acid

15

COMPOUND 22 (EXAMPLE 9)



20


3,6,9-tris(carboxymethyl)-14-[[[(3 β ,5 β ,7 α ,12 α)-7,12-dihydroxy-24-oxo-24-[(2-sulfoethyl)amino]-cholan-3-yl]-amino]-11,14-dioxo-3,6,9,12-tetraazatetradecanoic acid

25

30


31

COMPOUND 23 (EXAMPLE 9)




10 [(3 β ,5 β ,7 α ,12 α)-3-[[17-carboxy-10,13,16-tris(carboxymethyl)-1,8-dioxo-7,10,13,16-tetraazaheptadecyl]amino]-7,12-dihydroxy-cholan-24-oic acid

COMPOUND 24 (EXAMPLE 9)



(17S)-3,6,9-tris(carboxymethyl)-11-oxo-17-[[[(3 β ,5 β ,7 α ,12 α)-3,7,12-trihydroxy-24-oxocholan-24-yl]amino]-3,6,9,12-tetraazaoctadecanedioic acid

25 COMPOUND 25 (EXAMPLE 14)




32

[[[(3 β ,5 β ,7 α ,12 α)-3-[[[6-[[[bis[2-[bis(carboxymethyl)amino]ethyl]amino]acetyl]amino]-1-oxohexyl]amino]-7,12-dihydroxy-cholan-24-oic acid

COMPOUND 26 (EXAMPLE 14)

5




10

(3 β ,5 β ,7 α ,12 α)-3-[[[[[bis[2-[bis(carboxymethyl)amino]ethyl]amino]acetyl]amino]acetyl]amino]-7,12-dihydroxy-cholan-24-oic acid

COMPOUND 27 (EXAMPLE 14)

15




20

N⁶-[[bis[2-[bis(carboxymethyl)amino]ethyl]amino]acetyl]-N²-[(3 α ,5 β ,7 α ,12 α)-3,7,12-trihydroxy-24-oxocholan-24-yl]-L-lysine

25

COMPOUND 28 (EXAMPLE 15)

30




33

[[N⁶-[(4S)[4-[bis[2-[bis(carboxymethyl)amino]ethyl]amino]-4-carboxy]-1-oxobutyl]-N²-[(3 α ,5 β ,7 α ,12 α)-3,7,12-trihydroxy-24-oxocholan-24-yl]-L-lysine

COMPOUND 29 (EXAMPLE 15)

5

10




[3 β (S),5 β ,7 α ,12 α]-3-[4-carboxy-4-[bis[2-[bis(carboxymethyl)amino]ethyl]amino]-1-oxobutyl]amino]-7,12-dihydroxy-cholan-24-oic acid

15

COMPOUND 30 (EXAMPLE 16)

20




[[10-[2-[[2-[[[(3 β ,5 β ,7 α ,12 α)-7,12-dihydroxy-24-oxo-24-[(2-sulfoethyl)amino]cholan-3-yl]amino]-2-oxoethyl]amino]-2-oxoethyl]-1,4,7,10-tetraazacyclododecane-1,4,7-triacetic acid

25

COMPOUND 31 (EXAMPLE 16)


30



34


(3 β ,5 β ,7 α ,12 α)-3-[[[[[4,7,10-tris(carboxymethyl)-1,4,7,10-tetraazacyclododecyl]acetyl]amino]acetyl]amino]-7,12-dihydroxy-cholan-24-oic acid

COMPOUND 32 (EXAMPLE 16)




N²-[(3 α ,5 β ,7 α ,12 α)-3,7,12-trihydroxy-24-oxocholan-24-yl]-N⁶-[[4,7,10-tris(carboxymethyl)-1,4,7,10-tetraazacyclododecyl]acetyl]-L-lysine

COMPOUND 33 (EXAMPLE 16)



(3 β ,5 β ,7 α ,12 α)-3-[[6-[[[4,7,10-tris(carboxymethyl)-1,4,7,10-tetraazacyclododecyl]acetyl]amino]-1-oxohexyl]amino]-7,12-dihydroxy-cholan-24-oic acid

COMPOUND 34 (EXAMPLE 17)




35

[[[(3 α ,5 β ,7 α ,12 α)-3-[[[3-[4,7,10-tris(carboxymethyl)-
1,4,7,10-tetraazacyclododecyl]-2-hydroxypropyl]oxy]-
7,12-dihydroxy-cholan-24-oic acid

COMPOUND 35 (EXAMPLE 18)

5

10



[[[(3 β ,5 β ,7 α ,12 α)-3-[[[5-[4,7,10-tris(carboxymethyl)-
1,4,7,10-tetraazacyclododecyl]-4-hydroxy-1-oxopentyl]-
amino]-7,12-dihydroxy-cholan-24-oic acid

15 It is intended that all the matter contained in
the following section shall be interpreted as
illustrative and not in a limiting sense.

EXAMPLE 1

[[[4-Carboxy-5,8,11-tris(carboxymethyl)-1-[4-[[[(3 α ,
20 5 β ,7 α ,12 α)-3,7,12-trihydroxy-24-oxocholan-24-yl]amino]-
acetyl]amino]phenyl]-2-oxa-5,8,11-triazatridecan-13-oxa-
te(5 $^-$)]gadolate(2 $^-$)] hydrogen compound with 1-deoxy-
1-(methylamino)-D-glucitol (1:2)

A) N-[2-[(2-aminoethyl)amino]ethyl]-O-(4-nitrophe-
25 nyl)methyl-D,L-serine t-butyl ester

A solution of 14 g of t-butyl 2-bromo-3-[(4-
nitrophenyl)methoxy]propanoate (prepared according to
the procedure described by P. L. Rings et al., Synth.
Commun., 1993, 23, 2639) (0.0389 mol), in 30 ml of
30 acetonitrile was added with a solution of 20 g of
diethylenetriamine (0.19 mol) in 20 ml of acetonitrile

36

kept at 0-5°C and under inert atmosphere. The solution was then heated to 35°C for 4 h. The solvent was evaporated under vacuum and 100 ml of a NaCl saturated solution were added to the residue. The solution was
5 extracted with Et₂O; the organic phase was washed with H₂O, dried and concentrated under vacuum to obtain 12 g of the desired product (0.031 mol).

Yield: 80%

TLC: Carrier: silica gel plates 60 F₂₅₄ Merck

10 Eluent: CHCl₃ : CH₃OH : 25% NH₄OH (w/w) = 10:2:0.5 (v/v/v)

Detector: 0.5% KMnO₄ in 0.1N NaOH R_f = 0.5

The ¹H-NMR, ¹³C-NMR, IR and MS spectra are consistent with the indicated structure.

15 B) 4-[(1,1-dimethylethoxy)carbonyl]-5,8,11-tris[2-(1,1-dimethylethoxy)-2-oxoethyl]-1-(4-nitrophenyl)-2-oxa-5,8,11-triazatridecan-13-oic acid 1,1-dimethylethyl ester

A solution of 11 g of compound A) (0.029 mol) and
20 31.17 g of diisopropylethylamine (0.29 mol) in 50 ml of 1,2-dichloroethane, kept at 0-5°C and under inert atmosphere, was added with 28.28 g of t-butyl bromoacetate (0.145 mol). The reaction mixture was kept under stirring at room temperature for 16 h. After
25 cooling to 0°C, the solution was filtered and the solvent was evaporated under reduced pressure. The residue was taken up into AcOEt and H₂O. After evaporation of the solvent, the residue was purified by column chromatography, to obtain 14,8 g of the desired
30 product (0.018 mol).

Yield: 62%

37

TLC: Carrier: silica gel plates 60 F₂₅₄ Merck

Eluent: n-hexane : EtOAc = 7:3 (v/v)

Detector: 0.5% KMnO₄ in 0.1N NaOH $R_f = 0.5$

The ¹H-NMR, ¹³C-NMR, IR and MS spectra are consistent
5 with the indicated structure.

C) 4-[(1,1-dimethylethoxy)carbonyl]-5,8,11-tris[2-(1,1-dimethylethoxy)-2-oxoethyl]-1-(4-aminophenyl)-2-oxa-5,8,11-triazatridecan-13-oic acid 1,1-dimethylethyl ester

10 A solution of 13.7 g of compound B) (0.0163 mol) in 200 ml EtOH was added with 1.37 g of 10% palladium carbon and the mixture was hydrogenated at room temperature and normal pressure for 1 h. The suspension was filtered from the catalyst through Millipore^R (0.5
15 µm) and the solvent was evaporated under reduced pressure. The residue was purified by flash chromatography to obtain 10.7 g of the desired product (0.0132 mol).

Yield: 81%

20 HPLC titre: 99% (% area)

Stationary phase: column E. Merck Lichrosorb Select B 5 µm; 250 x 4 mm

Mobile phase: gradient elution

A = aqueous solution 0.01M KH₂PO₄ and 0.017M H₃PO₄

25 B = CH₃CN

min	% A	% B
0	95	5
30	20	80
35	95	5

30 Flow rate: 1 ml min⁻¹

Temperature: 45°C

38

Detector (UV): 245 nm

TLC: Carrier: silica gel plates 60 F₂₅₄ Merck

Eluent: n-hexane : Et₂O : i-PrOH = 70:25:5 (v/v/v)

Detector: UV lamp (254 nm) $R_f = 0.15$

5 The ¹H-NMR, ¹³C-NMR, IR and MS spectra are consistent with the indicated structure.

D) 4-[(1,1-dimethylethoxy)carbonyl]-5,8,11-tris[2-(1,1-dimethylethoxy)-2-oxoethyl]-1-[4-[[[(1,1-dimethylethoxy)carbonyl]amino]acetyl]amino]phenyl]-
10 2-oxa-5,8,11-triazatridecan-13-oic acid 1,1-dimethylethyl ester

A solution of 4.95 g of compound C) (0.0061 mol), and 2.13 g of N-(t-butoxycarbonyl)glycine (marketed product) (0.0122 mol) and 1.35 g of triethylamine (0.0134 mol) in 50 ml of DMF, kept under stirring at
15 0°C, was added drop by drop with 2.18 g of diethoxyphosphoryl cyanide (0.0134 mol), under inert atmosphere, in 15 minutes. When the addition was over, the mixture was left to warm to room temperature. After
20 120 h the mixture was diluted with AcOEt and washed with a NaCl saturated solution. The organic phase was then washed with a 10⁻⁵N HCl solution, with H₂O and evaporated under reduced pressure. The residue was purified by flash chromatography to obtain 3.02 g of
25 the desired product (0.0031 mol).

Yield: 51%

HPLC titre: 98% (in % area)

Stationary phase: column E. Merck Lichrosorb Select B, 5 µm; 250 x 4 mm

30 Mobile phase: gradient elution

A = aqueous solution 0.01M KH₂PO₄ and 0.017M H₃PO₄

39

B = CH₃CN

	min	% A	% B
	0	95	5
	30	20	80
5	45	20	80

Flow rate: 1 ml min⁻¹

Temperature: 45°C

Detector (UV): 245 nm

TLC: Carrier: silica gel plates 60 F₂₅₄ Merck10 Eluent: n-hexane : Et₂O : i-PrOH = 70:25:5 (v/v/v)Detector: UV lamp (254 nm) R_f = 0.15The ¹H-NMR, ¹³C-NMR, IR and MS spectra are consistent with the indicated structure.

E) 4-Carboxy-5,8,11-tris(carboxymethyl)-1-[4-[[[(-
 15 (3α,5β,7α,12α)-3,7,12-trihydroxy-24-oxocholan-24-
 yllamino]acetyl]amino]phenyl]-2-oxa-5,8,11-triaza-
 tridecan-13-oic acid

A solution of 35.09 g of compound D) (0.036 mol) and 270 ml of anisole in 340 ml of CH₂Cl₂ was added
 20 drop by drop, at 0°C, with 167 ml of trifluoroacetic acid in a time of 2 h. When the addition was over the mixture was left to warm to room temperature reacting for a 3 day total time. The reaction mixture was evaporated under reduced pressure. The residue was
 25 taken up into CH₂Cl₂. The residue was then suspended in H₂O, neutralized at 0°C with 25% NH₄OH (w/w) and extracted with ether ethyl. The aqueous phase was evaporated under reduced pressure to obtain a residue that was purified by flash chromatography. The
 30 resulting solid was dissolved at room temperature in a H₂O/DMF mixture (5 : 8 = v/v) and reacted with 21.85 g

40

of cholic acid N-succinimidyl ester (prepared according to the procedure described by Okahata, Y; Ando, R.; Kunitake, T., Bull. Chem. Soc. Jpn., 1979, 52, 3647-3653) (0.043 mol) added in small portions to the solution. After 30 h the reaction mixture was evaporated under reduced pressure and the residue was purified by flash chromatography. The product was dissolved in 1N HCl and eluted through an Amberlite^R XAD-16 polystyrene resin, to obtain 10.08 g of the desired product (0.010 mol).

Yield: 29% m.p.: 154-156°C (dec.)

K.F. titre: 1.79% (w/w)

HPLC titre: 98% (in % area)

Stationary phase: column E. Merck Lichrosorb Select B, 5 µm; 250 x 4 mm

Mobile phase: Gradient elution

A = aqueous solution 0.01M KH₂PO₄ and 0.017M H₃PO₄

B = CH₃CN

	min	% A	% B
20	0	95	5
	30	20	80
	45	20	80

Flow rate: 1 ml min⁻¹

Temperature: 45 °C

25 Detector (UV): 245 nm

Elemental analysis	C	H	N
% calc.:	59.06	7.54	7.18
% found:	58.22	7.78	7.13

TLC: Carrier: silica gel plates 60 F₂₅₄ Merck

30 Eluent: CH₂Cl₂ : MeOH : 25% NH₄OH (w/w) = 6:3:0.7 (v/v/v)

41

Detector: UV lamp (254 nm) or AcOH : conc. H_2SO_4 : p-anisaldehyde $R_f = 0.21$

The ^1H -NMR, ^{13}C -NMR, IR and MS spectra are consistent with the indicated structure.

5 F) Title compound

9.04 g of compound E) (8.9 mmol) were suspended in 200 ml of H_2O and pH was adjusted to 6.5 with 21.9 ml of 1N meglumine (21.9 mmol) to obtain a complete dissolution. Then a solution of 3.29 g of $\text{GdCl}_3 \cdot 6\text{H}_2\text{O}$ (8.9 mmol) in 40 ml of H_2O was dropped therein, maintaining at pH 6.5 by addition of 1N meglumine (43.7 ml total; 43.7 mmol); when pH remained constant without addition of meglumine, the mixture was filtered through a Millipore HA filter (0.45 μm) and subjected to nanofiltration. pH of the retentate was adjusted to 7 with meglumine and the solution was concentrated to dryness. The vitreous residue was ground and dried to obtain 13 g of the desired product (8.5 mmol).

Yield: 96% m.p.: 178-180°C (dec.)

20 K.F. titre: 6.84% (w/w)

HPLC titre: 98% (in % area)

Stationary phase: Column E. Merck Superspher RP 18; 5 μm ; 250 x 4 mm

Mobile phase: Gradient elution

25 A = 0.05 M KH_2PO_4 aqueous solution adjusted to pH 3.5 with H_3PO_4

B = CH_3CN

	min	% A	% B
	0	70	30
30	15	70	30
	30	50	50

42

Flow rate: 1 ml min⁻¹

Temperature: 40°C

Detector (UV): 245 nm

	Elemental analysis	C	H	Gd	N	Cl
5	% calc.:	48.96	6.89	10.34	6.45	
	% found:	45.88	7.12	9.70	6.06	< 0.1

The IR and MS spectra are consistent with the indicated structure.

EXAMPLE 2

10 [[4-Carboxy-5,8,11-tris(carboxymethyl)-1-[4-[[[(3 α ,5 β ,7 α ,12 α)-3,7,12-trihydroxy-24-oxocholan-24-yl]amino]phenyl]-2-oxa-5,8,11-triazatridecan-13-oate(5⁻)]gadolinate(2⁻)] hydrogen compound with 1-deoxy-1-(methylamino)-D-glucitol (1:2)

15 A) 4-[(1,1-dimethylethoxy)carbonyl]-5,8,11-tris[2-(1,1-dimethylethoxy)-2-oxoethyl]-1-[4-[[[(3 α ,5 β ,7 α ,12 α)-3,7,12-trihydroxy-24-oxocholan-24-yl]amino]phenyl]-2-oxa-5,8,11-triazatridecan-13-oic acid 1,1-dimethylethyl ester

20 A solution of 8.4 g of cholic acid (marketed product) (20.6 mmol) in 20 ml of DMF at 10°C, was added with 2.25 g of triethylamine (22.2 mmol) and 13.9 g of 4-[(1,1-dimethylethoxy)carbonyl]-5,8,11-tris[2-(1,1-dimethylethoxy)-2-oxoethyl]-1-(4-aminophenyl)-2-oxa-5,8,11-triazatridecan-13-oic acid 1,1-dimethylethyl ester (prepared according to the procedure described in EXAMPLE 1) (17.2 mmol) dissolved in 40 ml of DMF, to obtain a kind of gel. Then 4.19 g of diethoxyphosphoryl cyanide (23.9 mmol) in 5 ml of DMF were dropped therein, at 7°C and in 10 min. When the addition was over, the solution was homogeneous again. After 2 h at

25

30

43

7°C and 2 h at room temperature, the reaction mixture was poured into H₂O and extracted with Et₂O. The organic phase was washed with a 5% NaHCO₃ solution, then with a NaCl saturated solution, dried and
 5 evaporated under reduced pressure. The residue was purified by flash chromatography to obtain 9.5 g of the desired product (7.9 mmol).

Yield: 46%

HPLC titre: 92% (in % area)

10 Stationary phase: Column E. Merck Lichrosorb Select B;
 5 µm; 250 x 4 mm

Mobile phase: Gradient elution

A = 0.01M KH₂PO₄ and 0.017M H₃PO₄ aqueous solution

B = CH₃CN

15	min	% A	% B
	0	95	5
	30	20	80
	45	20	80

Flow rate: 1 ml min⁻¹

20 Temperature: 30 °C

Detector (UV): 245 nm

TLC: Carrier: silica gel plates 60 F₂₅₄ Merck

Eluent: AcOEt : i-PrOH= 95 : 5 (v/v)

Detector: UV lamp (254 nm) R_f= 0.42

25 The ¹H-NMR, ¹³C-NMR, IR and MS spectra are consistent with the indicated structure.

B) 4-Carboxy-5,8,11-tris(carboxymethyl)-1-[4-[[[(3α,-
 5β,7α,12α)-3,7,12-trihydroxy-24-oxocholan-24-yl]-
 amino]phenyl]-2-oxa-5,8,11-triazatridecan-13-oic
 30 acid

6.05 g of compound A) (5 mmol) were dissolved in

44

40 ml of CH_2Cl_2 , the solution was cooled to 0°C and 20 ml of CF_3COOH were dropped slowly (1 h). The reaction mixture was left under stirring at room temperature for 24 h, the solvent was evaporated off under reduced pressure and the residue, taken up into CH_2Cl_2 , was evaporated again to remove completely CF_3COOH . The resulting residue was taken up into CH_2Cl_2 and purified by flash chromatography. The product was dissolved in 1N HCl and eluted through an Amberlite^R XAD-16 polystyrene resin, to obtain 2.9 g of the desired product (3.15 mmol).

Yield: 60%

Elemental analysis C H N

% calc.: 60.11 7.68 6.09

15 % found: 58.65 7.43 5.99 H_2O 2.20

TLC: Carrier: silica gel plates 60 F₂₅₄ Merck

Eluent: CH_2Cl_2 : MeOH : 25% NH_4OH (w/w) = 6:3:0.7 (v/v/v)

Detector: UV lamp (254 nm) or AcOH : H_2SO_4 conc. : p-anisaldehyde R_f = 0.24

The ^1H -NMR, ^{13}C -NMR, IR and MS spectra are consistent with the indicated structure.

C) Title compound

According to the procedure described in EXAMPLE 1, 2 g of compound B) (2.17 mmol) in 45 ml of H_2O , were reacted with 0.80 g of $\text{GdCl}_3 \cdot 6\text{H}_2\text{O}$ (2.17 mmol), maintaining at pH 6.5 by addition of 10.74 ml of 1N meglumine. 3.08 g of the desired product (2.1 mmol) were obtained.

30 Yield: 97%

45

Elemental analysis	C	H	Gd	N	Cl
% calc.:	49.23	6.88	10.74	5.74	
% found:	46.84	6.47	10.15	5.43	< 0.1

The IR and MS spectra are consistent with the indicated structure.

EXAMPLE 3

[[[3,6,9-Tris(carboxymethyl)-10-(phenylmethoxy)methyl-11-oxo-14-[[[(3 α ,5 β ,7 α ,12 α)-3,7,12-trihydroxy-24-oxo-cholan-24-yl]amino]-3,6,9,12-tetraazatetradecanoate-(4⁻)]gadolinatate(1⁻)] hydrogen compound with 1-deoxy-1-(methylamino)-D-glucitol (1:1)

A) O-Phenylmethyl-N-[2-methoxy-2-oxoethyl]-N-[2-[[2-[bis(2-methoxy-2-oxoethyl)amino]ethyl](2-methoxy-2-oxoethyl)amino]ethyl]-D,L-serine

A suspension of 40 g of 4-carboxy-5,8,11-tris-(carboxymethyl)-1-phenyl-2-oxa-5,8,11-triazatridecan-13-oic acid (prepared as described in EP-A-230893; (0.07789 mol) in 400 ml of anhydrous MeOH, kept at 0°C, was added with 150 ml of thionyl chloride, in 2 h. The clear solution, heated to 25°C, was left under magnetic stirring for 30 h. The solution was evaporated to dryness and the resulting white solid, cooled in brine (-15°C), was added with 400 ml of Et₂O and, slowly and under stirring, with 500 ml of a NaHCO₃ saturated solution (pH 10). After separation, the aqueous phase, kept at 0°C, was acidified to pH 6.5 with 6N HCl and then extracted with EtOAc. The organic phase was evaporated to dryness. 23.4 g of the desired product (0.0411 mol) were obtained.

Yield: 53%

HPLC titre: 98% (in % area)

46

Stationary phase: Column E. Merck Lichrosorb Select B, 5 μ m; 250 x 4 mm;

Mobile phase: Gradient elution;

A = 0.01M KH_2PO_4 and 0.017M H_3PO_4 aqueous solution

5 B = CH_3CN

min	% A	% B
0	95	5
30	20	80
45	20	80

10 Flow rate: 1 ml min^{-1} ;

Temperature: 45 $^{\circ}\text{C}$;

Detector (UV): 210 nm, 254 nm and 280 nm.

TLC: Carrier: silica gel plates 60 F₂₅₄ Merck

Eluent: CH_2Cl_2 : MeOH = 8:2 (v:v)

15 Detector: 0.5% KMnO_4 in 0.1N NaOH R_f = 0.5

The ^1H -NMR, ^{13}C -NMR, IR and MS spectra are consistent with the indicated structure.

B) Methyl 3,6,9-tris(2-methoxy-2-oxoethyl)-10-(phenylmethoxy)methyl-11-oxo-14-[[[(3 α ,5 β ,7 α ,12 α)-3,7,-
20 12-trihydroxy-24-oxocholan-24-yl]amino]-3,6,9,12-tetraazatetradecanoate

A solution of 39.2 g of compound A) (0.0688 mol), 33.1 g of (3 α ,5 β ,7 α ,12 α)-N-(2-aminoethyl)-3,7,12-trihydroxycholan-24-amide (prepared according to the
25 procedure described by Hilton, M.L.; Jones, A.S.; Westwood, J.R.B. J. Chem. Soc., 3449-3453, 1955) (0.0734 mol) and 13.33 g of diethoxyphosphoryl cyanide (0.076 mol) in 400 ml of DMF was added drop by drop, at 0 $^{\circ}\text{C}$ and in 10 minutes, with 7.69 g of triethylamine
30 (0.076 mol). After 4 h at 0 $^{\circ}\text{C}$ and 16 h at room temperature, the reaction mixture was concentrated and

47

poured into a NaHCO_3 saturated solution and extracted with AcOEt . The organic phases were combined, washed with a NaCl saturated solution, with H_2O , dried over Na_2SO_4 and evaporated under reduced pressure. The solid
5 residue was purified by flash chromatography to obtain 25.2 g of the desired product (0.0251 mol).

Yield: 36%

HPLC titre: 91% (in % area)

Stationary phase: Column E. Merck Lichrosorb Select
10 B, 5 μm ; 250 x 4 mm

Mobile phase: Gradient elution

A = 0.01M KH_2PO_4 and 0.017M H_3PO_4 aqueous solution

B = CH_3CN

	min	% A	% B
15	0	95	5
	30	20	80
	45	20	80

Flow rate: 1 ml min^{-1}

Temperature: 30 $^{\circ}\text{C}$

20 Detector (UV): 210 nm

TLC: Carrier: silica gel plates 60 F_{254} Merck

Eluent: CH_2Cl_2 : MeOH : 25% NH_4OH (w/w) = 9:1:0.1
(v/v/v)

Detector: AcCH : Conc. H_2SO_4 : p-anisaldehyde = 100:2:1
25 (v/v/v) $R_f = 0.34$

The ^1H -NMR, ^{13}C -NMR, IR and MS spectra are consistent with the indicated structure.

C) Title compound

11.5 g of compound B) (11.4 mmol) were dissolved
30 in 1:1 $\text{MeOH}/\text{H}_2\text{O}$ (300 ml) and 2N NaOH (5 ml) was added until pH 12 was reached. The reaction mixture was

48

stirred for 48 h at room temperature maintaining at pH 12 by addition of 1N NaOH (35 ml) through a pH-stat apparatus. The reaction was monitored by HPLC. The resulting solution was adjusted to pH 7 with 2N HCl and evaporated. The residue was dissolved with 3:7 MeOH/H₂O (500 ml), acidified with 6N HCl (15 ml) and the solution was loaded onto an Amberlite^R XAD-16 resin column and eluted with a MeOH/H₂O gradient. Removal of the solvent from the fractions containing the product gave a solid that was further purified by reverse-phase preparative HPLC to give 2.13 g of 3,6,9-tris-(carboxymethyl)-10-(phenylmethoxy)methyl-11-oxo-14-[[[(3 α ,5 β ,7 α ,12 α)-3,7,12-trihydroxy-24-oxocholan-24-yl]-amino]-3,6,9,12-tetraazatetradecanoic acid (2.25 mmol) as a white solid. The acid was suspended in H₂O (100 ml) and MeOH (20 ml) and 1N meglumine (5.6 ml; 5.6 mmol) was added until a complete dissolution (pH 6.8). A solution of GdCl₃ 6H₂O (0.83 g; 2.23 mmol) in H₂O (20 mL) was added drop by drop to the reaction mixture, maintained at pH 6.8 by addition of 1N meglumine (8.4 ml; 8.4 mmol). After 16 h the cloudy solution was filtered, loaded onto an Amberlite^R XAD-16 resin column and eluted with a MeOH/H₂O gradient. The fractions containing the chelate were concentrated to dryness under reduced pressure to give the desired product (2.0 g; 1.5 mmol).

Yield 13% m.p. = >300

K.F. titre: 4.56% (w/w)

HPLC titre: 98% (in % area)

Stationary phase: Column E. Merck Superspher RP-18;
250 x 4 mm

49

Mobile phase: Gradient elution

A = aq. 0.05 M KH_2PO_4 B = CH_3CN

	min	% A	% B
5	0	70	30
	30	50	50

Flow rate: 1 ml min^{-1}

Temperature: 40°C

Detector (UV): 210 nm

10 Elemental analysis

	C	H	N	Gd
% calc.:	50.99	6.92	6.48	12.14
% found:	49.26	7.26	6.20	11.57

 $\text{H}_2\text{O} < 0.1$

The IR and MS spectra are consistent with the structure.

EXAMPLE 4

[[10-[2-Oxo-2-[[3-[[2-[[[(3 α ,5 β ,7 α ,12 α)-3,7,12-trihydroxy-24-oxocholan-24-yl]amino]ethyl]amino]propyl]amino]-ethyl]-1,4,7,10-tetraazacyclododecan-1,4,7-triacetoate-(3 $^-$)]gadolate(0)] hydrogen compound with HCl (1:1)

A) 2-(2-Aminoethyl)-1,3-dioxolane

A suspension of 50 g of 2-(2-bromoethyl)-1,3-dioxolane (product known in literature, CAS RN = 5754-35-8) (0.27 mL, 32.5 mol), 62.5 g of potassium phthalimide (0.34 mol), 9.16 g of $\text{Bu}_4\text{N}^+\text{HSO}_4^-$ (0.027 mol) in 150 ml of toluene was heated to 100°C and under N_2 stream for 3 h. After cooling to room temperature, the mixture was filtered and evaporated to dryness. By crystallization of the residue from abs. EtOH the phthalimido derivative was obtained. A solution of 58.5 g of $\text{NH}_2\text{NH}_2 \cdot \text{H}_2\text{O}$ (1.17 ml; 56.8 mol), 64.36 g of

50

phthalimido derivative (0.26 mol) in 2 l of abs. EtOH was heated to reflux under N₂ stream for 2.5 h. After cooling to 0°C, the precipitated phthalhydrazide was filtered through a sintered funnel. By evaporation of the filtrate to dryness, 23.26 g of the desired product (0.198 mol) were obtained.

Yield: 73%

Elemental analysis	C	H	N
% calc.:	51.25	9.48	11.94
10 % found:	49.27	9.77	10.53

The ¹H-NMR, ¹³C-NMR, IR and MS spectra are consistent with the indicated structure.

B) 2-[2-[(2-chloro-1-oxoethyl)amino]ethyl]-1,3-dioxo-lane

15 A solution of 23.0 g of compound A) (0.196 mol) and 19.8 g of Et₃N (0.196 mol; 27.16 ml) in 90 ml of CHCl₃ under N₂ stream was added with a solution of 22.17 g of chloroacetyl chloride (0.196 mol; 15.6 ml) in 60 ml of CHCl₃ keeping the temperature at 0-10°C.

20 When the reaction was completed, the reaction mixture was washed with H₂O and the aqueous phase was extracted with CHCl₃. The combined organic phases were dried and evaporated to dryness. By crystallization of the residue from Et₂O, 30.6 g of the desired product (0.158 mol) were obtained.

Yield: 81% m.p.: 62-63°C (dec.)

Elemental analysis	C	H	Cl	N
% calc.:	43.40	6.25	18.30	7.23
25 % found:	43.13	6.22	18.28	7.20

30 The ¹H-NMR, ¹³C-NMR, IR and MS spectra are consistent with the indicated structure.

51

C) N-[2-(1,3-dioxolan-2-yl)ethyl]-1,4,7,10-tetraaza-cyclododecane-1-acetamide

A solution of 203.3 g of 1,4,7,10-tetraazacyclododecane (marketed product) (1.18 mol) in 2 l CH₃CN was added at 80°C and under N₂ stream with a solution of 23 g of compound B) (0.118 mol) in 500 ml of CH₃CN in 2 h. When the reaction was over, the reaction mixture was concentrated and the precipitate (1,4,7,10-tetraazacyclododecane excess) was filtered off. The residue was evaporated to dryness and purified by column chromatography to obtain 36 g of the desired product (0.109 mol).

Yield: 93%

Elemental analysis	C	H	N
% calc.:	54.67	9.50	21.26
% found:	54.18	9.49	20.91

TLC: Carrier: silica gel plates 60 F₂₅₄ Merck

Eluent: CHCl₃ : MeOH : NH₄OH = 4:4:2

Detector: UV lamp (254 nm) or KMnO₄ in NaOH

R_f = 0.3

The ¹H-NMR, ¹³C-NMR, IR and MS spectra are consistent with the indicated structure.

D) 10-[2-oxo-2-[(3-oxopropyl)amino]ethyl]-1,4,7,10-tetraazacyclododecane-1,4,7-triacetic acid

48.6 g of bromoacetic acid (0.35 mol) were dissolved in 40 ml of H₂O and, keeping the temperature < 10°C, the pH of the solution was adjusted to 5 by addition of 175 ml of 2N NaOH. The solution, after addition of 35 g of compound C) (0.106 mol), was heated to 50°C for 5 h, maintaining at pH 10 by addition of 160 ml of 2N NaOH (0.32 mol). The reaction mixture was

52

added with 30 ml of 37% HCl to pH 2 and the solution was heated for 2 h at 50°C. The reaction mixture was salted off by electrodialysis and after evaporating the aqueous solution and drying the residue, 40 g of the
5 desired product (0.087 mol) were obtained.

Yield: 82% m.p.: 115-120°C

K.F. titre: 8.81% (w/w)

Elemental analysis	C	H	N
% calc.:	49.66	7.25	15.24
10 % found:	45.30	8.09	13.38

The ¹H-NMR, ¹³C-NMR, IR and MS spectra are consistent with the indicated structure.

E) 10-[2-Oxo-2-[[3-[[2-[[[(3 α ,5 β ,7 α ,12 α)-3,7,12-trihydroxy-24-oxocholan-24-yl]amino]ethyl]amino]propyl]amino]ethyl]-1,4,7,10-tetraazacyclododecan-
15 1,4,7-triacetic acid

A solution of 80 g of N-(2-aminoethyl)-(3 α ,5 β ,7 α ,12 α)-3,7,12-trihydroxycholan-24-amide (prepared according to the procedure described by Hilton, M.L.;
20 Jones, A.S.; Westwood, J.R.B., J. Chem. Soc. 1955, 3449-3453) (178 mmol) in 800 ml of anhydrous MeOH was added with 16.31 g of compound (D) (36 mmol), 35 ml of 1N HCl (35 mmol) and 1.49 g of NaBH₃CN (24 mmol). The solution was kept under nitrogen and magnetic stirring
25 and in the presence of molecular sieves (0.4 nm). After 50 h the solvent was evaporated off under reduced pressure to obtain a crude that was purified by flash chromatography. The product was dissolved in 1N HCl and eluted through an Amberlite^R XAD-16 polystyrene resin,
30 to obtain 8.79 g of the desired product (9.8 mmol).

Yield: 28% m.p.: 154°C

53

K.F. titre: 10.64% (w/w)

HPLC titre: 98.9% (in % area)

Stationary phase: Column E. Merck Lichrosorb Select
B; 5 μ m; 250 x 4 mm

5 Mobile phase: Gradient elution

A = 0.01M KH_2PO_4 and 0.017M H_3PO_4 aqueous solutionB = CH_3CN

	min	% A	% B
	0	95	5
10	30	20	80
	45	20	80

Flow rate: 1 ml min^{-1} Temperature: 45 $^{\circ}\text{C}$

Detector (UV): 210 nm

15	Elemental analysis	C	H	N
	% calc.:	60.44	8.91	10.97
	% found:	53.72	9.49	9.51

TLC: Carrier: silica gel plates 60 F₂₅₄ Merck

Eluent: CH_2Cl_2 : MeOH : 25% NH_4OH (w/w) = 7:3:1
20 (v/v/v)

Detector: AcOH : Conc. H_2SO_4 : p-anisaldehyde = 100:2:1
(v/v/v) R_f = 0.26

The ^1H -NMR, ^{13}C -NMR, IR and MS spectra are consistent
with the indicated structure.

25 F) Title compound

A solution of 6.40 g of compound (E) (7.2 mmol) in
60 ml of H_2O , kept at 50 $^{\circ}\text{C}$ with stirring and under
nitrogen atmosphere, was added with 1.18 g of GdO_3 (3.3
mmol). pH before the addition of the oxide was 6.65.

30 After that, 1N HCl (7.2 ml) was added and pH was
lowered to 2.75. The solution was filtered through a

54

Millipore filter (HAS 0.45 μm) and the solvent was evaporated off under reduced pressure, to obtain 6.90 g of the desired product (6.36 mmol).

Yield: 88.34% m.p.: 294°C (dec.)

5 Elemental analysis

	C	H	N	Gd	Cl	
% calc.:	49.82	7.15	9.04	14.50	3.27	
% found:	47.37	7.78	8.45	13.53	3.09	H ₂ O 6.44

TLC: Carrier: silica gel plates 60 F₂₅₄ Merck

10 Eluent: CHCl₃ : MeOH : H₂O : Et₃N = 8:2:0.1:0.1

Detector: AcOH : Conc. H₂SO₄ : p-anisaldehyde = 100:2:1
(v/v/v) R_f = 0.13

The IR and MS spectra are consistent with the indicated structure.

15 In the same way, the gadolinium complexes of the following ligands were prepared:

(3 β ,5 β ,7 α ,12 α)-7,12-dihydroxy-3-[[[3-[[[4,7,10-tris-(carboxymethyl)-1,4,7,10-tetraazacyclodec-1-yl]acetyl]-amino]propyl]amino]acetyl]amino]-cholan-24-oic acid

20 (Compound 8);

(3 β ,5 β ,7 α ,12 α)-7,12-dihydroxy-3-[[3-[[[4,7,10-tris(carboxymethyl)-1,4,7,10-tetraazacyclododec-1-yl]acetyl]-amino]propyl]amino]-cholan-24-oic acid (Compound 21).

EXAMPLE 5

25 [[(3 β ,5 β ,7 α ,12 α)-3-[[13-carboxy-6,9,12-tris(carboxymethyl)-1,4-dioxo-5-[(phenylmethoxy)methyl]-3,6,9,12-tetraazatridecyl]amino]-7,12-dihydroxy-cholan-24-oate-(5⁻)]gadolate(2⁻)] hydrogen compound with 1-deoxy-1-(methylamino)-D-glucitol (1:2)

30 A) (3 β ,5 β ,7 α ,12 α)-3-azido-7,12-dihydroxy-cholan-24-oic acid methyl ester

55

A solution of 2.06 g of cholic acid methyl ester (marketed product) (4.87 mmol), 1.28 g of triphenylphosphine (4.88 mmol) and 1.70 g of diethylazadicarboxylate (0.76 mL, 4.88 mmol) in 50 ml of THF, at room temperature and under inert atmosphere, was added with a solution of 1.4 g of diphenylphosphorylazide (1.1 mL, 5.11 mmol) in 5 ml of THF during 15 minutes. After 24 hours at room temperature, 1 equivalent of diethylazadicarboxylate (0.76 mL, 4.88 mmol) and 1 equivalent of triphenylphosphine (1.28 g, 4.88 mmol) were added. After a further 24 hours the solvent was evaporated off under reduced pressure and the resulting crude was purified by flash chromatography. 1.6 g of the desired product (3.57 mmol) was obtained.

Yield: 73%

Elemental analysis	C	H	N
% calc.:	67.08	9.23	9.38
% found:	66.86	9.30	9.15

H₂O 0.74

TLC: Carrier: silica gel plates 60 F₂₅₄ Merck

Eluent: AcOEt : hexane = 1:1

Detector: AcOH : Conc. H₂SO₄ : p-anisaldehyde = 100:2:1
(v/v/v) R_f = 0.56The ¹H-NMR, ¹³C-NMR, IR and MS spectra are consistent with the indicated structure.B) (3 β ,5 β ,7 α ,12 α)-3-amino-7,12-dihydroxy-cholan-24-oic acid methyl ester

A solution of 28.28 g of compound A) ester methyl (0.063 mol) in 100 ml of THF was added with 5 ml of H₂O and 16.59 g of triphenylphosphine (0.063 mol). After 96 h at room temperature, the reaction mixture was

56

evaporated under reduced pressure and the residue was purified by flash chromatography, to obtain 23.21 g of the desired product (0.055 mol).

Yield 87%.

5 Elemental analysis C H N
 % calc.: 71.29 10.39 3.32
 % found: 70.06 10.57 3.41 H₂O 0.26
 TLC: Carrier: silica gel plates 60 F₂₅₄ Merck
 Eluent: MeOH : Et₃N = 95:5

10 Detector: AcOH : Conc. H₂SO₄ : p-anisaldehyde = 100:2:1
 (v/v/v) R_f = 0.36

The ¹H-NMR, ¹³C-NMR, IR and MS spectra are consistent with the indicated structure.

15 C) (3β,5β,7α,12α)-3-[[[(phenylmethoxy)carbonyl]amino]acetyl]amino]-7,12-dihydroxy-cholan-24-oic acid methyl ester

 A solution of 12.25 g of carbobenzyloxyglycine (marketed product) (58.5 mmol) and 6 g of N-methylmorpholine (59.3 mmol) in 400 ml of THF was added drop
 20 by drop, under nitrogen and at -4°C, with 8 g of isobutyl chloroformate (58.4 mmol) and subsequently 21.8 g of compound B) (51.7 mmol) dissolved in 100 ml of THF. After 30 min at -4°C the reaction mixture was filtered and evaporated under reduced pressure. The
 25 residue was taken up into Et₂O and H₂O; the organic phase was separated, washed with H₂O, dried over Na₂SO₄ and evaporated under reduced pressure. The solid residue was purified by flash chromatography, to obtain 27.9 g of the desired product (45.5 mmol).

30 Yield: 88%.

57

Elemental analysis	C	H	N	
% calc.:	68.59	8.55	4.57	
% found:	68.27	8.74	4.52	H ₂ O 0.25

TLC: Carrier: silica gel plates 60 F₂₅₄ Merck

5 Eluent: MeOH : Et₃N = 95:5

Detector: AcOH : Conc. H₂SO₄ : p-anisaldehyde = 100:2:1
(v/v/v) R_f = 0.85

The ¹H-NMR, ¹³C-NMR, IR and MS spectra are consistent with the indicated structure.

10 D) (3β,5β,7α,12α)-3-(aminoacetyl)amino-7,12-dihydroxy-cholan-24-oic acid methyl ester

A solution of compound C) methyl ester in MeOH was added with 10% Pd/C and the mixture was hydrogenated at room temperature and pressure, to obtain the desired product.

15 E) (3β,5β,7α,12α)-3-[[[13-carboxy-6,9,12-tris(carboxymethyl)-1,4-dioxo-5-[(phenylmethoxy)methyl]-3,6,9,12-tetraazatridecyl]amino]-7,12-diidroxycholan-24-oic acid

20 According to the procedure described in EXAMPLE 3, O-phenylmethyl-N-[2-methoxy-2-oxoethyl]-N-[2-[[[2-[bis(2-methoxy-2-oxoethyl)amino]ethyl](2-methoxy-2-oxoethyl)amino]ethyl]-D,L-serine and compound D) were condensed, in DMF and triethylamine, with

25 diethoxyphosphoryl cyanide. When the reaction was over, the reaction mixture was poured into a NaHCO₃ saturated solution and extracted with AcOEt. The organic phases were combined and evaporated under reduced pressure. The residue was dissolved in MeOH and hydrolysed with a

30 LiOH monohydrate aqueous solution. The reaction mixture was evaporated to dryness, the solid residue was

58

dissolved in 1N HCl and eluted through an Amberlite^R XAD-16 polystyrene resin, to obtain the desired product.

5 The ¹H-NMR, ¹³C-NMR, IR and MS spectra are consistent with the indicated structure.

F) Title compound

According to the procedure described in EXAMPLE 1, compound E) was reacted with GdCl₃.6H₂O in H₂O, maintaining at pH 6.5 by addition of 1N meglumine. The
10 desired product was obtained.

The IR and MS spectra are consistent with the indicated structure.

In the same way, the gadolinium complexes of the following ligands were prepared:

15 3,6,9-Tris(carboxymethyl)-14-[[[(3β,5β,7α,12α)-7,12-dihydroxy-24-oxo-24-[(2-sulfoethyl)amino]cholan-3-yl]amino]-11,14-dioxo-10-(phenylmethoxy)methyl-3,6,9,12-tetraazatetradecanoic acid (COMPOUND 15);

20 N-[(3β,5β,7α,12α)-3-[[[13-carboxy-6,9,12-tris(carboxymethyl)-1,4-dioxo-5-[(phenylmethoxy)methyl]-3,6,9,12-tetraazatridecyl]amino]-7,12-dihydroxy-24-oxocholan-24-yl]glycine (COMPOUND 16);

(3β,5β,7α)-3-[[[13-carboxy-6,9,12-tris(carboxymethyl)-1,4-dioxo-5-[(phenylmethoxy)methyl]-3,6,9,12-tetraazatridecyl]amino]-7-hydroxy-cholan-24-oic acid (COMPOUND
25 17);

(3β,5β,12α)-3-[[[13-carboxy-6,9,12-tris(carboxymethyl)-1,4-dioxo-5-[(phenylmethoxy)methyl]-3,6,9,12-tetraazatridecyl]amino]-12-hydroxy-cholan-24-oic acid (COMPOUND
30 18);

(3β,5β)-3-[[[13-carboxy-6,9,12-tris(carboxymethyl)-1,4-

dioxo-5-[(phenylmethoxy)methyl]-3,6,9,12-tetraazatridecylamino]-cholan-24-oic acid (COMPOUND 19);

(3 β ,5 β ,7 α ,12 α)-3-[[17-carboxy-10,13,16-tris(carboxymethyl)-1,8-dioxo-9-[(phenylmethoxy)methyl]-7,10,13,16-tetraazaheptadecyl]amino]-7,12-dihydroxy-cholan-24-oic acid (COMPOUND 20).

EXAMPLE 6

[[[(3 β ,5 β ,7 α ,12 α)-3-[[17-carboxy-10,13,16-tris(carboxymethyl)-8-oxo-9-[(phenylmethoxy)methyl]-3,7,10,13,16-pentaazaheptadecyl]oxy]-7,12-dihydroxy-cholan-24-oate-(5⁻)]gadolinate(2⁻)] hydrogen compound with 1-deoxy-1-(methylamino)-D-glucitol(1:2)

A) 2-Chloro-N-[2-(1,3-dioxolan-2-yl)ethyl]-3-phenylmethoxypropanamide

A solution of 69.63 g of 2-chloro-3-(phenylmethoxy)propanoyl chloride (prepared according to the procedure described in Inorg. Chem., 31. 2422, 1992) (0.299 mol) in 90 ml of CHCl₃ was added to a solution of 35.49 g of 2-(2-aminoethyl)-1,3-dioxolane (prepared according to the procedure described in EXAMPLE 4) (0.303 mol) and to 60.3 g of triethylamine (83 ml; 0.596 mol) in 100 ml of CHCl₃ under inert atmosphere, keeping the temperature at 0-5°C. The reaction mixture was stirred for 5 h at 25°C, then was washed with H₂O. The organic phase was dried and evaporated to dryness, the residue was purified by flash chromatography. 61.68 g of the desired product (0.197 mol) were obtained.

Yield: 66%

TLC: Carrier: silica gel plates 60 F₂₅₄ Merck

Eluent: AcOEt : n-hexane = 1 : 1 (v/v)

Detector: 0.5% KMnO₄ in 0.1N NaOH

R_f = 0.34

60

The ^1H -NMR, ^{13}C -NMR, IR and MS spectra are consistent with the indicated structure.

B) 5,8,11-tris[2-(1,1-dimethylethoxy)-2-oxoethyl]-1-phenyl-4-[[2-(1,3-dioxolan-2-yl)ethyl]amino]carbonyl-2-oxa-5,8,11-triazatridecan-13-oic acid (1,1-dimethylethyl) ester

30.97 g of diethylenetriamine (0.300 mol) were added to a solution of 20.94 g of compound A) (0.067 mol) in 100 ml of MeCN under inert atmosphere and the mixture was kept at 50°C for 72 h and at 80°C for 8 h. After cooling to 0°C, the precipitate (diethylenetriamine hydrochloride) was filtered and washed with 50 ml of MeCN. After evaporating the solvent under reduced pressure, the diethylenetriamine excess was distilled off under vacuum. The crude was taken up into 80 ml of AcOEt, filtered and evaporated to dryness to obtain a residue, that was purified by column chromatography [silica gel; eluent CHCl_3 : MeOH : NH_3 25% (w/w) = 20:4:0.4 (v/v/v). 12.61 g of 2-[[2-[(2-aminoethyl)amino]ethyl]amino]-3-(phenylmethoxy)-N-[2-(1,3-dioxolan-2-yl)ethyl]propanamide (0.03 mol) were obtained, that was used directly in the subsequent step (46% yield).

A solution of 7.50 g of 2-[[2-[(2-aminoethyl)amino]ethyl]amino]-3-(phenylmethoxy)-N-[2-(1,3-dioxolan-2-yl)ethyl]propanamide in 30 ml of 1,2-dichloroethane was added, under inert atmosphere, with 20.64 g of diisopropylethylamine (0.160 mol) and, keeping the temperature from 0 to 5°C, with 15.58 g of t-butyl bromoacetate (0.080 mol). The solution was kept at 15°C for 24 h, added with further t-butyl bromoacetate (4.25 g; 0.022 mol) and kept for 72 h at 15°C. The solution

61

was cooled to 0°C and filtered. The filtrate was concentrated, taken up into H₂O and extracted with AcOEt. The organic phase was washed with H₂O, dried and evaporated to dryness to obtain a crude that was

5 purified by column chromatography [silica gel 935 g; eluent: AcOEt : n-hexane 1:1 (v/v)]. The fractions of similar purity were combined and evaporated to dryness to obtain the desired product (5.18 g; 0.062 mmol). Yield: 34%.

10 Yield: 16% on two steps

TLC: Carrier: silica gel plates 60 F₂₅₄ Merck

Eluent: AcOEt : n-hexane = 1 : 1

Detector: 0.5% KMnO₄ in 0.1N NaOH R_f = 0.21

The ¹H-NMR, ¹³C-NMR, IR and MS spectra are consistent

15 with the indicated structure.

C) 5,8,11-tris(carboxymethyl)-1-phenyl-4-[(3-oxopropyl)amino]carbonyl-2-oxa-5,8,11-triazatridecan-13-oic acid

67 ml of 1N HCl (0.067 mol) were added to a

20 solution of 14 g of compound B) (0.017 mol) in 280 ml of dioxane. The solution was diluted with 215 ml of H₂O, stirred at 35°C for 54 h, then at 4°C for 48 h. After evaporation of the dioxane, the aqueous solution was extracted with AcOEt. The organic phase was washed

25 with H₂O, then dried and evaporated to dryness. The residue was taken up into CH₂Cl₂ and the solution was evaporated to dryness. The residue was taken up into CH₂Cl₂ and the solution was added, in about 1 h, with 82 g of trifluoroacetic acid (55.7 ml; 0.719 mol). The

30 solution was kept at 5°C for 24 h under inert atmosphere, then was evaporated to dryness. The residue

62

was taken up into CH_2Cl_2 and evaporated to dryness, repeating the procedure several times. The crude was taken up into CH_2Cl_2 and extracted with H_2O . The aqueous phase was separated, evaporated to small volume and chromatographed by HPLC. 1.5 g of the desired product (2.64 mmol) were obtained.

Yield: 16% m.p.: 100-102°C (dec.)

K.F. titre: 2.27% (w/w)

HPLC titre: 97% (in % area)

10 Stationary phase: Column E. Merck Lichrosorb RP-Select B 5 μm ; 250 x 4 mm;

Mobile phase: Gradient elution;

A = 0.01M KH_2PO_4 and 0.017M H_3PO_4 aqueous solution

B = A / CH_3CN = 3:7

15	min	% A	% B
	0	90	10
	30	10	90
	40	10	90

Flow rate: 1.5 ml min^{-1} ;

20 Temperature: 35 °C;

Detector (UV): 210 nm.

Elemental analysis

	C	H	N	Na	Cl	H_2O
% calc.:	52.81	6.38	9.85			
25 % found:	51.82	6.34	9.62	< 0.10	< 0.10	2.27

The ^1H -NMR, ^{13}C -NMR, IR and MS spectra are consistent with the indicated structure.

D) (3 β ,5 β ,7 α ,12 α)-3-[[17-carboxy-10,13,16-tris(carboxymethyl)-8-oxo-9-[(phenylmethoxy)methyl]-3,7,10,-
30 13,16-pentaazaheptadecyl]oxy]-7,12-dihydroxycho-
lan-24-oic acid

63

According to the procedure described in EXAMPLE 4, compound C) and (3 β ,5 β ,7 α ,12 α)-3-[2-(amino)ethoxy]-7,12-dihydroxycholan-24-oic acid (prepared according to the procedure described in EP-A-417725), were reacted, in anhydrous MeOH and HCl, with NaBH₃CN, under inert atmosphere. The desired product was obtained. The ¹H-NMR, ¹³C-NMR, IR and MS spectra are consistent with the indicated structure.

E) Title compound

According to the procedure described in EXAMPLE 1, compound D) was reacted with GdCl₃.6H₂O in H₂O, maintaining at pH 6.5 by addition of 1N meglumine. The desired product was obtained.

The IR and MS spectra are consistent with the indicated structure.

EXAMPLE 7

[[[(3 β ,5 β ,7 α ,12 α)-7,12-dihydroxy-3-[2-[[[4-[4,12-bis(carboxy)-5,8,11-tris(carboxymethyl)-2-oxa-5,8,11-triazadodecyl]phenyl]amino]thioxomethyl]amino]ethoxy]-cholan-24-oate(6⁻)]gadolate(3⁻)] hydrogen compound with 1-deoxy-1-(methylamino)-D-glucitol (1:3)

A) (3 β ,5 β ,7 α ,12 α)-7,12-dihydroxy-3-[2-[[[4-[4,12-bis(carboxy)-5,8,11-tris(carboxymethyl)-2-oxa-5,8,11-triazadodecyl]phenyl]amino]thioxomethyl]-amino]ethoxy]-cholan-24-oic acid

A solution of 4-[(1,1-dimethylethoxy)carbonyl]-5,8,11-tris[2-(1,1-dimethylethoxy)-2-oxoethyl]-1-(4-aminophenyl)-2-oxa-5,8,11-triazatridecan-13-oic acid 1,1-dimethylethyl ester (prepared according to the procedure described in EXAMPLE 1) in CHCl₃ was added with 1,1'-thiocarbonyl diimidazole (marketed product)

and subsequently with (3 β ,5 β ,7 α ,12 α)-3-[2-(amino)ethoxy]-7,12-dihydroxy-cholan-24-oic acid (prepared according to the procedure described in EP-A-417725). The reaction mixture was then evaporated and the residue dissolved in CH₂Cl₂ and hydrolysed with CF₃COOH to give the desired product.

The ¹H-NMR, ¹³C-NMR, IR and MS spectra are consistent with the indicated structure.

B) Title compound

According to the procedure described in EXAMPLE 1, compound A) was reacted with GdCl₃.6H₂O in H₂O, maintaining at pH 6.5 by addition of 1N meglumine. The desired product was obtained.

The IR and MS spectra are consistent with the indicated structure.

EXAMPLE 8

[[3,6,9-Tris(carboxymethyl)-10-[(phenylmethoxy)methyl]-11-oxo-17-[[[(3 α ,5 β ,7 α ,12 α)-3,7,12-trihydroxy-24-oxocholan-24-yl]amino]-3,6,9,12-tetraazaoctadecanedioate-(5⁻)]gadolate(2⁻)] dihydrogen compound with 1-deoxy-1-(methylamino)-D-glucitol (1:2)

A) N⁶-(phenylmethoxy)carbonyl-N²-[(3 α ,5 β ,7 α ,12 α)-3,7,12-trihydroxy-24-oxocholan-24-yl]-L-lysine methyl ester

A suspension of cholic acid (16.3 g; 40 mmol) and triethylamine (4.86 g; 48 mmol) in THF (350 ml), kept at 0°C under nitrogen atmosphere, was added drop by drop with isobutyl chloroformate (6.56 g; 48 mmol) in 10 min. After 30 min a solution of N⁶-(phenylmethoxy)carbonyl-L-lysine (marketed product) (11.2 g; 40 mmol) in 0.67 N NaOH (60 ml) was dropped

65

therein during 20 min. The reaction mixture was kept at 0°C for one more hour and then at room temperature for 5 h. A 2N HCl aqueous solution was added to the mixture until acid pH, then the organic solvent was evaporated off under reduced pressure. The residual aqueous suspension was diluted with a NaCl saturated solution and extracted with AcOEt. The organic phases were combined, dried and evaporated to dryness, recovering a solid that was powdered and dried over P₂O₅ under reduced pressure. The resulting crude product was subjected to the subsequent reaction, without further purification procedures.

A solution of N⁶-(phenylmethoxy)carbonyl-N²-[(3α,5β,7α,12α)-3,7,12-trihydroxy-24-oxocholan-24-yl]-L-lysine (27.5 g) in MeOH (600 ml), kept at room temperature and under nitrogen atmosphere, was added with p-toluenesulfonic acid monohydrate (1.56 g; 8.2 mmol). After 20 h the reaction mixture was added with Et₃N (0.832 g; 8.2 mmol). The mixture was evaporated under reduced pressure and the resulting crude was purified by flash chromatography to obtain the desired product (24.1 g; 35.2 mmol).

Yield: 88% m.p.: 80-83°C

K.F. titre: 1.37% (w/w)

25 HPLC titre: 99.5% (in % area)

Stationary phase: Column E. Merck Lichrosorb Select B; 5 µm; 250 x 4 mm

Mobile phase: Gradient elution

A = 0.01M KH₂PO₄ and 0.017M H₃PO₄ aqueous solution

30 B = CH₃CN

66

min	% A	% B
0	95	5
30	20	80
45	20	80

5 Flow rate: 1 ml min⁻¹

Temperature: 45 °C

Detector (UV): 210 nm

[α]_D²⁰: + 16.2° (c 2.1; MeOH)

Elemental analysis C H N

10 % calc.: 68.39 8.83 4.09

% found: 66.82 9.01 3.73

TLC: Carrier: silica gel plates 60 F₂₅₄ Merck

Eluent: AcOEt : i-PrOH = 9:1 (v/v)

Detector: AcOH : Conc. H₂SO₄ : p-anisaldehyde = 100:2:1

15 (v/v/v) R_f = 0.22

The ¹H-NMR, ¹³C-NMR, IR and MS spectra are consistent with the indicated structure.

B) N²-[(3α,5β,7α,12α)-3,7,12-trihydroxy-24-oxocholan-24-yl]-L-lysine methyl ester monohydrochloride

20 A solution of 15.0 g of compound A) (21.9 mmol) in MeOH (150 ml) was added with Pd/C (1.5 g). The mixture was hydrogenated at room temperature and pressure. The transformation was monitored by TLC and HPLC. After 1.5 h the reaction mixture was filtered through paper
25 filter and the filtrate was cooled to 0°C in a H₂O/ice bath and added with a HC solution in MeOH (20.5 ml; 23.2 mmol). The solution was evaporated under reduced pressure and the residue was powdered and dried under reduced pressure to obtain the desired product (12.4 g;
30 21.1 mmol).

Yield: 96%

m.p.: 108-110°C

67

K.F. titre: 2.20% (w/w)

HPLC titre: 92.4% (in % area)

Stationary phase: Column E. Merck Lichrosorb Select
B; 5 μ m; 250 x 4 mm

5 Mobile phase: Gradient elution

A = 0.01M KH_2PO_4 and 0.017M H_3PO_4 aqueous solutionB = CH_3CN

	min	% A	% B
	0	95	5
10	30	20	80
	45	20	80

Flow rate: 1 ml min^{-1}

Temperature: 45 °C

Detector (UV): 210 nm

15 $[\alpha]_{20}^D = +14.4^\circ$ (c 2.16, MeOH)

Elemental analysis	C	H	N	Cl
% calc.:	63.40	9.44	4.77	6.04
% found:	62.01	9.89	4.59	5.93

TLC: Carrier: silica gel plates 60 F₂₅₄ Merck20 Eluent: MeOH : Et_3N = 95:5 (v/v)Detector: AcOH : Conc. H_2SO_4 : p-anisaldehyde = 100:2:1
(v/v/v) $R_f = 0.33$ The ^1H -NMR, ^{13}C -NMR, IR and MS spectra are consistent
with the indicated structure.25 C) 3,6,9-Tris(carboxymethyl)-10-[(phenylmethoxy)methyl]-11-oxo-17-[[[(3 α ,5 β ,7 α ,12 α)-3,7,12-trihydroxy-24-oxocholan-24-yl]amino]-3,6,9,12-tetraazaoctadecanedioic acid9.35 g of compound B) (14.3 mmol), O-phenylmethyl-
30 N-(2-methoxy-2-oxoethyl)-N-[2-[[2-[bis(2-methoxy-2-oxoethyl)amino]ethyl](2-methoxy-2-oxoethyl)amino]ethyl]-

68

D,L-serine (prepared as described in Example 3) (9.28 g; 14.3 mmol) and BOP-reagent (marketed product) (6.32 g; 14.3 mmol) were dissolved in DMF (140 ml) at room temperature. N,N-Diisopropylethylamine (8.51 ml; 50.1 mmol) was added to this stirred solution in 15 min. The reaction was monitored by HPLC. After 6 h the reaction mixture was evaporated under reduced pressure and the residue was dissolved in EtOAc. The solution was successively washed with saturated aqueous NH_4Cl , H_2O up to neutral pH, dried and evaporated under reduced pressure. The solid residue was purified by flash chromatography to obtain a yellow-brown solid that was dissolved in 2:1 MeOH/ H_2O and 1N NaOH (1.5 ml) was added until pH 12 was reached. The reaction mixture was stirred for 21 h at room temperature maintaining at pH 12 by addition of 1N NaOH (35.5 ml) through a pH-stat apparatus. The reaction was monitored by HPLC. The resulting solution was adjusted to pH 6.5 with 1N HCl and evaporated under reduced pressure. The residue was dissolved in 7:3 1N HCl/MeOH and the solution was loaded onto an Amberlite^R XAD-16.00 resin column and eluted with a MeOH/ H_2O gradient. The fractions containing the ligand were concentrated to dryness under reduced pressure giving the desired product (4.51 g; 4.37 mmol).

Yield: 31% m.p.: 158-160°C

K.F.: 4.13% (w/w)

HPLC: 97% (area %)

Stationary phase: Column E. Merck Lichrosorb Select B; 5 μm ; 250 x 4 mm

Mobile phase: Gradient elution

69

A = aqueous solution 0.01 M in KH_2PO_4 and 0.017 M in H_3PO_4

B = CH_3CN

	min	% A	% B
5	0	95	5
	30	20	80
	45	20	80

Flow rate: 1 ml min⁻¹

Temperature: 45 °C

10 Detector (UV): 210 nm

Elemental analysis	C	H	N	Cl
% calc.:	60.50	7.91	6.79	0.00
% found:	58.13	8.22	6.33	<0.1

TLC: Silica gel plates 60 F₂₅₄ (E. Merck art. 5719)

15 Eluent: 80:30:5:5 = CHCl_3 : MeOH : H_2O : Et_3N

Detection: AcOH : Conc. H_2SO_4 : p-anisaldehyde = 100 : 2 : 1 (v/v/v) R_f = 0.25

The ^1H -NMR, ^{13}C -NMR, IR and MS spectra are consistent with the structure.

20 D) Title compound

3.52 g of compound C) (3.20 mmol) were suspended in 9 : 1 H_2O /MeOH (70 ml) at 50°C and under nitrogen. Meglumine (1.241 g; 6.357 mmol) was added obtaining complete dissolution. Gd_2O_3 (0.581 g; 1.60 mmol) was added to the reaction mixture and the resulting suspension was stirred for 21 h at 50°C. The almost clear solution was filtered through Millipore^R apparatus (HAS 0.45 µm filter) and the filtrate was adjusted to pH 7 with 1% meglumine solution (0.90 ml; 9.0 mg; 4.6 µmol). The solution was evaporated to dryness under reduced pressure to obtain a solid that

70

was pulverized and dried under reduced pressure giving the desired product (4.90 g; 3.11 mmol).

Yield 94% m.p. 170 - 175°C (160°C, sint.)

K.F. titre: 2.15% (w/w)

5 HPLC titre: 97% (area %)

Stationary phase: Column E. Merck Superspher RP-18;
250 x 4 mm

Mobile phase: Isocratic elution: 74 : 26 A/B

A = 0.05 M aqueous solution in KH_2PO_4

10 B = CH_3CN

Flow rate: 1 ml min^{-1}

Temperature: 45°C

Detector (UV): 210 nm

Elemental analysis	C	H	N	Gd
15 % calc.:	50.27	7.16	6.22	9.97
% found:	49.77	7.49	6.07	9.68

TLC: Silica gel plates 60 F₂₅₄ (E. Merck art. 5719)

Eluent: 80 : 30 : 5 : 5 CHCl_3 : MeOH : H_2O : Et_3N

Detection: AcOH : Conc. H_2SO_4 : p-anisaldehyde = 100 :

20 2 : 1 (v/v/v) $R_f = 0.33$

The IR and MS spectra are consistent with the structure.

EXAMPLE 9

25 [[(3 β ,5 β ,7 α ,12 α)-3-[[13-carboxy-6,9,12-tris(carboxymethyl)-1,4-dioxo-3,6,9,12-tetraaazatridecyl]amino]-7,12-dihydroxy-cholan-24-oate(5⁻)]gadolate(1⁻)] hydrogen compound with 1-deoxy-1-(methylamino)-D-glucitol (1:2)

A) (3 β ,5 β ,7 α ,12 α)-3-[[13-Carboxy-6,9,12-tris(carboxymethyl)-1,4-dioxo-3,6,9,12-tetraaazatridecyl]amino]-7,12-dihydroxy-cholan-24-oic acid

30

A suspension of diethyleneetriaminepentaacetic

dianhydride (marketed product) (0.142 mol) in DMF (850 ml) at 80°C, was added drop by drop with a solution of H₂O (0.211 mol) and DMF (50 ml). After 1.5 h. a solution of (3 β ,5 β ,7 α ,12 α)-3-(aminoacetyl)amino-7,12-dihydroxy-cholan-24-oic acid methyl ester (prepared according to the procedure of EXAMPLE 5) (0.0356 mol) in DMF (100 ml) was dropped therein. When the addition was over, the mixture was cooled to 20°C and 2N NaOH (360 ml) was dropped therein. After 24 h the mixture was adjusted to pH 7 with 37% HCl and the solution was evaporated under vacuum. The residue was dissolved with MeOH/H₂O=3/7 (500 ml) and with 37% HCl (7 ml). The resulting solution was loaded on an Amberlite^R XAD-16 resin and eluted with a MeOH/H₂O gradient to obtain the desired product.

The ¹H-NMR, ¹³C-NMR, IR and MS spectra are consistent with the indicated structure.

B) Title compound

According to the procedure described in EXAMPLE 1, compound A) was reacted with GdCl₃.6H₂O in H₂O, maintaining at pH 6.5 by addition of 1N meglumine. The desired product was obtained.

The IR and MS spectra are consistent with the indicated structure.

In the same way, the gadolinium complexes of the following ligands were prepared:

3,6,9-Tris(carboxymethyl)-14-[[(3 β ,5 β ,7 α ,12 α)-7,12-dihydroxy-24-oxo-24-[(2-sulfoethyl)amino]-cholan-3-yl]amino]-11,14-dioxo-3,6,9,12-tetraazatetradecanoic acid (COMPOUND 22);
[(3 β ,5 β ,7 α ,12 α)-3-[[17-carboxy-10,13,16-tris(carboxyme-

thyl)-1,8-dioxo-7,10,13,16-tetraazaheptadecyl]amino]-
 7,12-dihydroxy-cholan-24-oic acid (COMPOUND 23);
 (17S)-3,6,9-Tris(carboxymethyl)-11-oxo-17-[[[(3 β ,5 β ,7 α ,
 12 α)-3,7,12-trihydroxy-24-oxocholan-24-yl]amino]-3,6,-
 5 9,12-tetraazaoctadecanedioic acid (COMPOUND 24).

EXAMPLE 10

[(3 β ,5 β ,7 α ,12 α)-(3' β ,5' β ,7' α ,12' α)-3,3'-[[[6,9,12-tris-
 (carboxymethyl)-1,4,14,17-tetraoxo-3,6,9,12,15-penta-
 azaheptadecan-1,17-diyl]bisimino]bis[7,12-dihydroxycho-
 10 lan-24-oate(5⁻)]gadolate(2⁻)] hydrogen compound with
 1-deoxy-1-(methylamino)-D-glucitol (1:2)

A) (3 β ,5 β ,7 α ,12 α)-(3' β ,5' β ,7' α ,12' α)-3,3'-[[[6,9,12-
 tris(carboxymethyl)-1,4,14,17-tetraoxo-3,6,9,12,-
 15-pentaazaheptadecan-1,17-diyl]bisimino]bis[7,12-
 15 dihydroxy-cholan-24-oic] acid

Diethylenetriamino pentaacetic acid dianhydride
 (marketed product) was reacted in DMF with two
 equivalents of (3 β ,5 β ,7 α ,12 α)-3-(aminoacetyl)amino-
 7,12-dihydroxycholan-24-oic acid methyl ester (prepared
 20 according to the procedure described in Example 5). The
 reaction mixture was subsequently treated with a LiOH
 monohydrate aqueous solution, evaporated and the
 residue was dissolved in 1N HCl and eluted through an
 Amberlite^R XAD-16 polystyrene resin, to obtain the
 25 desired product.

The ¹H-NMR, ¹³C-NMR, IR and MS spectra are consistent
 with the indicated structure.

B) Title compound

According to the procedure described in EXAMPLE 1,
 30 compound A) was reacted with GdCl₃.6H₂O in H₂O,
 maintaining at pH 6.5 by addition of 1N meglumine. The

desired product was obtained.

The IR and MS spectra are consistent with the indicated structure.

EXAMPLE 11

5 [[[(3 β (S),5 β ,7 α ,12 α)-7,12-dihydroxy-3-[[4-[[[5-[bis[2-[bis(carboxymethyl)amino]ethyl]amino]-5-carboxypentyl]-amino]thioxomethyl]amino]benzoyl]amino]-cholan-24-oate(6⁻)]gadolate(3⁻)] hydrogen compound with 1-deoxy-1-(methylamino)-D-glucitol (1:3)

10 A) N²-Bis[2-[bis(carboxymethyl)amino]ethyl]-L-lysine

This product was synthesized starting from N⁶-(phenylmethoxy)carbonyl-L-lysine (marketed product) analogously to what described by M. A. Williams and H. Rapoport, J. Org. Chem. 1993, 58, 1151-1158 for the 4-nitro-L-phenylalanine.

The ¹H-NMR, ¹³C-NMR, IR and MS spectra are consistent with the indicated structure.

20 B) [(3 β (S),5 β ,7 α ,12 α)-7,12-dihydroxy-3-[[4-[[[5-[bis[2-[bis(carboxymethyl)amino]ethyl]amino]-5-carboxypentyl]amino]thioxomethyl]amino]benzoyl]amino]-cholan-24-oic acid

25 A solution of (3 β ,5 β ,7 α ,12 α)-3-amino-7,12-dihydroxycholan-24-oic acid (prepared according to the procedure described in EP-A-417725) in DMF and triethylamine was added with an equimolecular amount of 4-isothiocyanatobenzoyl chloride (prepared according to the procedure described by N. Viswanathan and R. C. Desai, Indian J. Chem., 1981. 20B, 308-310). After (3 β ,5 β ,7 α ,12 α)-3-amino-7,12-dihydroxycholan-24-oic acid
30 had been completely converted, compound A) was added to the reaction mixture. When the reaction was over, the

solvent was evaporated off and the residue was dissolved in 1N HCl and eluted through an Amberlite^R XAD-16 polystyrene resin, to obtain the desired product.

- 5 The ¹H-NMR, ¹³C-NMR, IR and MS spectra are consistent with the indicated structure.

C) Title compound

According to the procedure described in EXAMPLE 1, compound B) was reacted with GdCl₃.6H₂O in H₂O, maintaining at pH 6.5 by addition of 1N meglumine. The
10 desired product was obtained.

The IR and MS spectra are consistent with the indicated structure.

EXAMPLE 12

- 15 [[[(3β(S),5β,7α,12α)-7,12-dihydroxy-3-[[4-[[5-[bis[2-bis(carboxymethyl)amino]ethyl]amino]-5-carboxypentyl]-amino]-1,4-dioxobutyl]amino]-cholan-24-oate(6⁻)]gadolinate(3⁻)] hydrogen compound with 1-deoxy-1-(methyl-amino)-D-glucitol (1:3)

- 20 A) (3β,5β,7α,12α)-3-[(3-carboxy-1-oxopropyl)amino]-7,12-dihydroxycholan-24-oic acid methyl ester

A solution of 6.15 g of (3β,5β,7α,12α)-3-amino-7,12-dihydroxycholan-24-oic acid methyl ester (prepared according to the procedure described in EXAMPLE 5) (15
25 mmol) in 85 ml of THF and 17 ml of triethylamine was added with 1.5 g of succinic anhydride (15 mmol). After 4 h at room temperature the reaction mixture was poured into 200 ml of 1N HCl and extracted with AcOEt. The organic phase was washed with H₂O, dried and evaporated
30 under reduced pressure. The residue was purified by flash chromatography, to obtain 4.5 g of the desired

75

product (8.6 mmol).

Yield: 57% m.p.: 92-94°C

Elemental analysis C H N

% calc.: 66.76 9.08 2.68

5 % found: 65.45 9.40 2.50 0.56 H₂OTLC: Carrier: silica gel plates 60 F₂₅₄ Merck

Eluent: AcOEt : AcOH = 4:1

Detector: AcOH : Conc. H₂SO₄ : p-anisaldehydeR_f = 0.47

10 The ¹H-NMR, ¹³C-NMR, IR and MS spectra are consistent with the indicated structure.

B) (3β,5β,7α,12α)-3-[[4-[(2,5-dioxo-1-pyrrolidinyl)-oxy]-1,4-dioxobutyl]amino]-7,12-dihydroxy-cholan-24-oic acid methyl ester

15 A solution of compound A) in anhydrous THF and anhydrous acetonitrile was added with N-hydroxysuccinimide and subsequently with dicyclohexylcarbodiimide: dicyclohexylurea precipitated and was filtered off. The solution was evaporated under reduced pressure

20 to obtain the desired product.

The ¹H-NMR, ¹³C-NMR, IR and MS spectra are consistent with the indicated structure.

C) [3β(S),5β,7α,12α]-7,12-dihydroxy-3-[[4-[[5-[bis[2-bis(carboxymethyl)amino]ethyl]amino]-5-carboxypentyl]amino]-1,4-dioxobutyl]amino]-cholan-24-oic acid

25

A solution of compound B) in DMF was added with a solution of N²-bis[2-[bis(carboxymethyl)amino]ethyl]-L-lysine (prepared according to the procedure described

30 in Example 11) in DMF and triethylamine. After 24 h, the reaction mixture was added with a LiOH monohydrate

aqueous solution, then the solvent was evaporated and the residue was dissolved in 1N HCl and eluted through an Amberlite^R XAD-16 polystyrene resin, to obtain the desired product.

- 5 The ¹H-NMR, ¹³C-NMR, IR and MS spectra are consistent with the indicated structure.

D) Title compound

According to the procedure described in EXAMPLE 1, compound C) was reacted with GdCl₃.6H₂O in H₂O, maintaining at pH 6.5 by addition of 1N meglumine. The
10 desired product was obtained.

The ¹H-NMR, ¹³C-NMR, IR and MS spectra are consistent with the indicated structure.

EXAMPLE 13

- 15 [[(3β,5β,7α,12α)-7,12-dihydroxy-3-[[4-[[2-[[4-[4,12-bis(carboxy)-5,8,11-tris(carboxymethyl)-2-oxa-5,8,11-triazadodecyl]phenyl]amino]-2-oxoethyl]amino]-1,4-dioxobutyl]amino]-cholan-24-oate(6⁻)]gadolate(3⁻)] hydrogen compound with 1-deoxy-1-(methylamino)-D-glucitol (1:3)
20

A) (3β,5β,7α,12α)-7,12-dihydroxy-3-[[4-[[2-[[4-[4,12-bis(carboxy)-5,8,11-tris(carboxymethyl)-2-oxa-5,8,11-triazadodecyl]phenyl]amino]-2-oxoethyl]amino]-1,4-dioxobutyl]amino]-cholan-24-oic acid

- 25 A solution of 4-[(1,1-dimethylethoxy)carbonyl]-5,8,11-tris[2-(1,1-dimethylethoxy)-2-oxoethyl]-1-[4-[[[(1,1-dimethylethoxy)carbonyl]amino]acetyl]amino]-phenyl]-2-oxa-5,8,11-triazatridecan-13-oic acid 1,1-dimethylethyl ester (prepared according to the
30 procedure described in EXAMPLE 1) in anisole and CH₂Cl₂ was treated with trifluoroacetic acid. After 3 days the

reaction mixture was evaporated under reduced pressure, the residue was taken up into CH_2Cl_2 and evaporated again, repeating said procedure 2 more times. The residue was then suspended in H_2O , neutralized at 0°C with 25% NH_4OH (w/w) and extracted with ethyl ether. The aqueous phase was evaporated under reduced pressure to obtain a residue that was purified by flash chromatography. The resulting solid was dissolved in DMF and triethylamine and said solution was added with the succinimido derivative of (3 β ,5 β ,7 α ,12 α)-3-[[4-[(2,5-dioxo-1-pyrrolidinyl)oxy]-1,4-dioxobutyl]amino]-7,12-dihydroxy-cholan-24-oic acid methyl ester (prepared according to the procedure described in Example 12). After 24h the reaction mixture was added with a LiOH monohydrate aqueous solution, then the solvent was evaporated and the residue was dissolved in 1N HCl and eluted through an Amberlite^R XAD-16 polystyrene resin, to obtain the desired product. The ^1H -NMR, ^{13}C -NMR, IR and MS spectra are consistent with the indicated structure.

B) Title compound

According to the procedure described in EXAMPLE 1, compound A) was reacted with $\text{GdCl}_3 \cdot 6\text{H}_2\text{O}$ in H_2O , maintaining at pH 6.5 by addition of 1N meglumine. The desired product was obtained.

The IR and MS spectra are consistent with the indicated structure.

EXAMPLE 14

[[[(3 β ,5 β ,7 α ,12 α)-3-[[[6-[[[bis[2-[bis(carboxymethyl)amino]ethyl]amino]acetyl]amino]-1-oxohexyl]amino]-7,12-dihydroxy-cholan-24-oate(5⁻)]gadolate(2⁻)] hydrogen

78

compound with 1-deoxy-1-(methylamino)-D-glucitol (1:2)

A) N-[bis[2-[bis[[2-(1,1-dimethylethoxy)-2-oxoethyl]-amino]ethyl]glycine

1 g of glycine (marketed product) (0.0133 mol) was
5 dissolved in 100 ml of H₂O/EtOH (25/75) and a solution
of NaOH 1N (8.8 mL, 8.8 mmol) was added until pH = 10
was reached. Then a solution of 10 g of N-(2-
bromoethyl)-N-[2-(1,1-dimethylethoxy)-2-oxoethyl]glyci-
ne 1,1 dimethylethyl ester (prepared according to
10 Williams, M., A. et al., J. Org. Chem., 1993, 58, 1151)
(0.0284 mmol) in 10 ml of 95% EtOH was added. After
keeping the reaction at room temperature for 18 h., the
mixture was evaporated to dryness. The residue was
purified by flash chromatography obtaining 6 g of the
15 desired product (0.010 mol).

Yield 73%

TLC: Silica gel plates 60 F₂₅₄ (E. Merck art. 5719)

Eluent: 1 : 9 = MeOH : AcOH

Detection: 0.5% KMnO₄ in 0.1N NaOH R_f = 0.20

20 The ¹H-NMR, ¹³C-NMR, IR and MS spectra are consistent
with the structure.

B) (3β,5β,7α,12α)-3-[[[6-[(phenylmethoxy)carbonyl]-
amino]1-oxohexyl]amino]-7,12-dihydroxy-cholan-24-
oic acid methyl ester

25 A solution of 3.46 g of N-Cbz-6-aminohexanoic acid
(commercially available from Lancaster) (0.0130 mol) in
70 ml of THF and 1.8 ml of TEA (1.31 g, 0.0130 mol) was
added, very quickly, with 1.77 g of isobutyl
chloroformate (marketed product) (1.7 mL, 0.0130 mol)
30 keeping the temperature at 0-3°C. After 15 min. 5 g of
(3β,5β,7α,12α)-3-amino-7,12-dihydroxy-cholan-24-oic

79

acid methyl ester (prepared according to Example 5) (0.119 mol) in 30 ml of THF were added. After 30 min. from the end of dropping the temperature was kept at room temperature and the reaction mixture was filtered through a sintered glass filter and evaporated under reduced pressure. The solid was dissolved in CH_2Cl_2 and washed with H_2O and brine. The phases were separated and the organic one was evaporated. The residue was dissolved in CH_2Cl_2 and washed with a saturated solution NaHCO_3 and H_2O . The organic layers were combined, dried and evaporated under reduced pressure to give a solid, that was crystallized by AcOEt, obtaining the desired product (4.7 g, 0.0070 mol).

Yield: 60%

HPLC: 98.5 % (area %)

Stationary phase: Column E. Merck Lichrosorb Select B; 5 μm ; 250 x 4 mm

Mobile phase: Gradient elution

A = 0.01 M aqueous solution in KH_2PO_4 and 0.017 M in H_3PO_4
 B = CH_3CN

	min	% A	% B
	0	95	5
	30	20	80
	45	20	80

Flow rate: 1 ml min⁻¹

Temperature: 45 °C

Detector (UV): 210 nm

Elemental analysis	C	H	N	
% calc.:	70.03	9.04	4.19	
% found:	69.82	9.08	4.18	H_2O 0.24

80

TLC: Silica gel plates 60 F₂₅₄ (E. Merck art. 5719)

Eluent: AcOEt : i-PrOH = 95 : 5 (v/v)

Detection: AcOH : Conc. H₂SO₄ : p-anisaldehyde = 100 :
2 : 1 (v/v/v) $R_f = 0.41$

5 The ¹H-NMR, ¹³C-NMR, IR and MS spectra are consistent
with the structure.

C) (3 β ,5 β ,7 α ,12 α)-3-[(6-amino-1-oxohexyl)amino]-7,12-
dihydroxy-cholan-24-oic acid methyl ester

4 g of compound B) (0.00598 mol) were dissolved in
10 50 ml of EtOH abs. and 800 mg of Pd/C were added. The
hydrogenation was performed at room temperature and
atmospheric pressure. When the reaction has terminated,
the mixture was filtered and evaporated to dryness. The
residue was purified by flash chromatography obtaining
15 the desired product (2.7 g, 0.005 mol).

Yield: 84.4%

HPLC: 95 % (area %)

Stationary phase: Column E. Merck Lichrosorb Select
B; 5 μ m; 250 x 4 mm

20 Mobile phase: Gradient elution

A = aqueous solution 0.01 M in KH₂PO₄ and 0.017 M
in H₃PO₄

B = CH₃CN

	min	% A	% B
25	0	95	5
	30	20	80
	45	20	80

Flow rate: 1 ml min⁻¹

Temperature: 45 °C

30 Detector (UV): 210 nm

TLC: Silica gel plates 60 F₂₅₄ (E. Merck art. 5719)

81

Eluent: MeOH : TEA = 95 : 5 (v/v)

Detection: AcOH : Conc. H₂SO₄ : p-anisaldehyde = 100 :
2 : 1 (v/v/v) $R_f = 0.33$

The ¹H-NMR, ¹³C-NMR, IR and MS spectra are consistent
5 with the structure.

D) (3 β ,5 β ,7 α ,12 α)-3-[[6-[[[Bis[2-[bis(carboxymethyl)-
amino]ethyl]amino]acetyl]amino]-1-oxohexyl]amino]-
7,12-dihydroxy-cholan-24-oic acid

Equimolecular amounts of compound A) and of
10 compound C) were reacted at room temperature with
benzotriazol-1-yloxy-tris(dimethylamino)phosphonium he-
xafluorophosphate (BOP, marketed product) in DMF and in
the presence of a N,N-diisopropylethylamine excess.
When the reaction was over, the reaction mixture was
15 evaporated under vacuum and the residue taken up into
EtOAc. The solution was washed with a NH₄Cl saturated
solution and with H₂O to neutral pH, then evaporated.
The residue was hydrolysed first with 1M NaOH in
MeOH/H₂O then with CF₃COOH in CH₂Cl₂, to give the
20 desired product that was purified and salted off by
elution on an Amberlite^R XAD-16 resin using a MeOH/H₂O
gradient.

The ¹H-NMR, ¹³C-NMR, IR and MS spectra are consistent
with the indicated structure.

25 E) Title compound

According to the procedure described in EXAMPLE 1,
compound A) was reacted with GdCl₃.6H₂O in H₂O,
maintaining at pH 6.5 by addition of 1N meglumine. The
desired product was obtained, that was salted off by
30 elution with a MeOH/H₂O gradient on an Amberlyte XAD-16
resin.

The IR and MS spectra are consistent with the indicated structure.

In the same way the gadolinium complexes of the following ligands were prepared:

5 (3 β ,5 β ,7 α ,12 α)-3-[[[[[bis[2-[bis(carboxymethyl)amino]ethyl]amino]acetyl]amino]acetyl]amino]-7,12-dihydroxy-cholan-24-oic acid (COMPOUND 26);

N⁶-[[bis[2-[bis(carboxymethyl)amino]ethyl]amino]acetyl]-N²-[(3 α ,5 β ,7 α ,12 α)-3,7,12-trihydroxy-24-oxocholan-24-yl]-L-lysine (COMPOUND 27);

EXAMPLE 15

15 [[N⁶-[(4S)[4-[Bis[2-[bis(carboxymethyl)amino]ethyl]-amino]-4-carboxy]-1-oxobutyl]-N²-[(3 α ,5 β ,7 α ,12 α)-3,7,12-trihydroxy-24-oxocholan-24-yl]-L-lysinate(6⁻)]-gadolate(3⁻)] hydrogen compound with 1-deoxy-1-(methylamino)-D-glucitol (1:3)

A) N,N-Bis[2-[bis[2-(1,1-dimethylethoxy)-2-oxoethyl]-amino]ethyl]-L-glutamic 1-(1,1-dimethylethyl) ester 5-(phenylmethyl)ester

20 132.01 g of 1-(1,1-dimethylethyl) ester 5-(phenylmethyl)ester L-glutamic acid (prepared according to Helv. Chim. Acta, 199, 1864, 1958) (0.45 mol) were dissolved in 200 ml of H₂O and 1L of EtOH and added to 320.2 g of N-(2-bromoethyl)-N-[2-(1,1-dimethylethoxy)-2-oxoethyl]glycine 1,1 dimethylethyl ester (prepared

25 according to Williams, M., A. et al., J. Org. Chem., 58, 1151. 1993) (0.909 mol) maintaining at pH 8 by addition of 10N NaOH. After 50h at 5°C, temperature was brought to 20°C for a further 80h and to 50°C for 5h.

30 The mixture was adjusted to pH 7 with conc. HCl, evaporated and extracted with hexane; the organic phase

83

was concentrated and the residue was purified by flash chromatography to obtain the desired product (75.2 g, 0.09 mol).

Yield: 20%

5 TLC: Silica gel plates 60 F₂₅₄ (E. Merck art. 5719)

Eluent: hexane : AcOEt = 2 : 1 (v/v)

Detection: 0.5% KMnO₄ in 0.1N NaOH $R_f = 0.76$

The ¹H-NMR, ¹³C-NMR, IR and MS spectra are consistent with the structure.

10 B) N,N-Bis[2-[bis[2-(1,1-dimethylethoxy)-2-oxoethyl]-amino]ethyl]-L-glutamic acid 1-(1,1-dimethylethyl) ester

15 15.05 g of compound A) (18 mmol) dissolved in 100 ml of EtOH were added with 4 g of 5% wet Pd/C and the mixture was hydrogenated under a H₂ pressure of 111.36 kPa. When the reaction was over, the mixture was filtered, concentrated to a residue and purified by flash chromatography obtaining the desired product (11.01 g, 14.76 mmol).

20 Yield: 82%

TLC: Silica gel plates 60 F₂₅₄ (E. Merck art. 5719)

Eluent: AcOEt

Detection: 0.5% KMnO₄ in 0.1N NaOH $R_f = 0.85$

25 The ¹H-NMR, ¹³C-NMR, IR and MS spectra are consistent with the structure.

C) N⁶-[(4S)[4-[Bis[2-[bis(carboxymethyl)amino]ethyl]-amino]-4-carboxy]-1-oxobutyl]-N²-[(3 α ,5 β ,7 α ,12 α)-3,7,12-trihydroxy-24-oxocholan-24-yl]-L-lysine

30 Equimolecular amounts of compound B) and N²-[(3 α ,5 β ,7 α ,12 α)-3,7,12-trihydroxy-24-oxocholan-24-yl]-L-lysine methyl ester monohydrochloride (prepared as

84

described in EXAMPLE 8) were reacted at room temperature with BOP in DMF and in the presence of a N,N-diisopropylethylamine excess. When the reaction was over, the reaction mixture was evaporated under vacuum and the residue taken up with EtOAc. The solution was washed with a NH₄Cl saturated solution and with H₂O to a neutral pH, then evaporated. The residue was hydrolysed first with 1M NaOH in MeOH/H₂O, then with CF₃COOH in CH₂Cl₂ to give the desired product that was purified and salted off by elution on an Amberlite^R XAD-16 resin using a MeOH/H₂O gradient. The ¹H-NMR, ¹³C-NMR, IR and MS were consistent with the structure.

D) Title compound

According to the procedure described in EXAMPLE 1, compound B) was reacted with GdCl₃.6H₂O in H₂O, maintaining at pH 6.5 by addition of 1N meglumine. The resulting product was salted off by elution with a MeOH/H₂O gradient on an Amberlite^R XAD-16 resin. The IR and MS spectra are consistent with the structure.

In the same way the gadolinium complex of the following ligand was prepared:

[3β(S),5β,7α,12α]-3-[4-carboxy-4-[bis[2-[bis(carboxymethyl)amino]ethyl]amino]-1-oxobutyl]amino]-7,12-dihydroxy-cholan-24-oic acid (COMPOUND 29);

EXAMPLE 16

[[10-[2-[[2-[[[3β,5β,7α,12α]-7,12-dihydroxy-24-oxo-24-[(2-sulfoethyl)amino]cholan-3-yl]amino]-2-oxoethyl]amino]-2-oxoethyl]-1,4,7,10-tetraazacyclododecane-1,4,7-triacetoate(4⁻)]gadolate(1⁻)] hydrogen compound with

1-deoxy-1-(methylamino)-D-glucitol (1:1)

A) 1,4,7,10-Tetraazacyclododecane-1,4,7-triacetic acid tris(1,1-dimethylethyl)ester monohydrochloride

5 A stirred solution of 90 g of 10-formyl-1,4,7,10-tetraazacyclododecane-triacetic acid tris(1,1-dimethylethyl)ester (prepared according to EP-A-292689) (0.166 mol) in 1L of anhydrous EtOH was added with 12.24 g of hydroxylamine hydrochloride (0.1826 mol) and refluxed
10 under argon atmosphere for 18 hours. At the end of this time, the reaction mixture was cooled and ethanol was removed under reduced pressure. To the resulting solid, CH₂Cl₂ was added and the suspension was transferred to a separatory funnel. After washing with water and
15 brine, the organic phase was separated, dried and concentrated under reduced pressure to obtain a residue. The solid was recrystallized twice from a CH₂Cl₂ / hexane mixture and dried under in a vacuum oven at 35°C for 18 hours to obtain 57 g of the desired
20 product (0.103 mol).

Yield 62.3%

Elemental analysis	C	H	N	Cl	
% calc.:	55.21	9.25	9.84	7.49	
% found:	55.40	9.43	9.84	7.48	H ₂ O 1.41

25 TLC: Silica gel plates 60 F₂₅₄ (E. Merck art. 5719)

Eluent: 95 : 5 = MeOH : AcOH

Detection: 0.5% KMnO₄ in 0.1N NaOH R_f = 0.67

The ¹H-NMR, ¹³C-NMR, IR and MS spectra are consistent with the structure.

30 B) (3β,5β,7α,12α)-3-[[[(1,1-dimethylethoxy)carbonyl]amino]acetyl]amino]-7,12-dihydroxy-cholan-24-

86

oic acid methyl ester

To a solution of N-(t-butoxycarbonyl)glycine (marketed product) (14.7 g; 84.0 mmol) and Et₃N (8.50 g; 11.6 ml; 84.0 mmol) in THF (400 ml), at 0°C and under nitrogen, was added dropwise isobutyl chloroformate (11.5 g; 10.9 ml; 84.0 mmol). After 15 min a solution of (3β,5β,7α,12α)-3-amino-7,12-dihydroxy-cholan-24-oic acid methyl ester (prepared according to Example 5) (29.5 g; 70.0 mmol) in THF (100 ml) was added dropwise to the reaction mixture at 0°C. After 20 min the reaction mixture was allowed to rise room temperature and stirred overnight. The suspension was filtered through a sintered funnel and the filtrate was evaporated off under reduced pressure to give a residue that was dissolved in Et₂O and washed with a saturated aqueous solution of NaHCO₃ and H₂O. The organic phase was separated, dried and then evaporated under reduced pressure. The solid residue was purified by flash chromatography to give the desired product as a white solid (25.3 g; 43.7 mmol).

Yield: 62% m.p.: 110-114°C

K.F.: 0.75 %

HPLC: 97 % (area %)

Stationary phase: Column E. Merck Lichrosorb Select B; 5 μm; 250 x 4 mm

Mobile phase: Gradient elution

A = aqueous solution 0.01 M in KH₂PO₄ and 0.017 M in H₃PO₄

B = CH₃CN

30

87

min	% A	% B
0	95	5
30	20	80
45	20	80

- 5 Flow rate: 1 ml min⁻¹
 Temperature: 45 °C
 Detector (UV): 210 nm
 Elemental analysis C H N
 % calc.: 66.40 9.40 4.84
 10 % found: 64.97 9.07 4.60
 TLC: Silica gel plates 60 F₂₅₄ (E. Merck art. 5719)
 Eluent: EtOAc : i-PrOH = 9:1 (v/v)
 Detection: AcOH : Conc. H₂SO₄ : p-anisaldehyde =
 100:2:1 (v/v/v) R_f = 0.43
 15 The ¹H-NMR, ¹³C-NMR, IR and MS spectra are consistent
 with the structure.
 C) (3β,5β,7α,12α)-3-[[[(1,1-dimethylethoxy)carbo-
 nyl]amino]acetyl]amino]-7,12-dihydroxy-cholan-24-
 oic acid
 20 To a solution of compound B) (24.5 g; 41.1 mmol)
 in MeOH/H₂O (2:1, v/v; 160 ml) at room temperature, was
 added dropwise 1N NaOH (49.7 ml; 49.7 mmol) in 2 hours.
 After 48 h the reaction mixture was filtered through a
 sintered glass filter and evaporated under reduced
 25 pressure. The residue was treated with 0.5 N HCl/EtOAc
 (1:2, 240 ml) and pH of the resulting mixture was
 adjusted to 2 with 2N HCl (10 ml) under vigorous
 stirring. After separation the aqueous phase was
 saturated with NaCl and extracted with EtOAc. The
 30 organic layers were combined, dried and evaporated
 under reduced pressure obtaining the desired product

88

(22.2 g, 39.3 mmol).

Yield: 96% m.p.: 150-155°C

K.F.: 0.75 %

Acidic titre (0.1 N NaOH): 95 %

5 HPLC: 96 % (area %)

Stationary phase: Column E. Merck Lichrosorb Select
B; 5 µm; 250 x 4 mm

Mobile phase: Gradient elution

A = aqueous solution 0.01 M in KH_2PO_4 and 0.017 M
10 in H_3PO_4
B = CH_3CN

	min	% A	% B
	0	95	5
	30	20	80
15	45	20	80

Flow rate: 1 ml min⁻¹

Temperature: 45 °C

Detector (UV): 210 nm

Elemental analysis	C	H	N
20 % calc.:	65.92	9.28	4.96
% found:	65.41	9.98	4.60

TLC: Silica gel plates 60 F₂₅₄ (E. Merck art. 5719)

Eluent: EtOAc : i-PrOH : AcOH = 90 : 15 : 1 (v/v)

Detection: AcOH : Conc. H_2SO_4 : p-anisaldehyde =
25 100:2:1 (v/v/v) R_f = 0.47

The ¹H-NMR, ¹³C-NMR, IR and MS spectra are consistent
with the structure.

D) 2-[[[(3β,5β,7α,12α)-3-[[[(1,1-dimethylethoxy)car-
bonyl]amino]acetyl]amino]-7,12-dihydroxy-24-oxo-
30 cholan-24-yl]amino]ethanesulfonic acid
Taurine (2-aminoethanesulfonic acid) (marketed

product) (5.40 g; 43.1 mmol) and Et₃N (5.16 g; 7.07 ml; 51.0 mmol) were added to a solution of compound C) (22.1 g; 39.1 mmol) and (2-ethoxy-1-ethoxycarbonyl-1,2-dihydroquinoline, REDQ) (marketed product) (12.6 g; 51.0 mmol) in DMF (100 ml) under nitrogen. The resulting suspension was heated at 90°C for 70 min. obtaining a clear solution which was then cooled to 25°C. After 30 min the reaction mixture was poured slowly into cold Et₂O (0°C, 900 ml): a resinous product was formed. The suspension was kept at 4°C overnight. The mixture was decanted and the resinous substance was washed with Et₂O, treated with CH₂Cl₂ and filtered to remove unreacted taurine. The filtrate was poured into cold Et₂O (0°C) the precipitate was filtered through a sintered glass filter and immediately dissolved in 0.4 N NaOH in MeOH (100 ml). After diluting the solution with Et₂O, the suspension was kept at 4°C for several hours and then filtered through a sintered glass filter. The solid was washed thoroughly with Et₂O and dried under reduced pressure to give the desired product (24.7 g; 35.6 mmol).

Yield: 91% m.p.: 150-155°C

TLC: Silica gel plates 60 F₂₅₄ (E. Merck art. 5719)

Eluent: CHCl₃: MeOH : AcOH = 90 : 30 : 4 (v/v/v)

Detection: AcOH : Conc. H₂SO₄ : p-anisaldehyde = 100 : 2 : 1 (v/v/v) R_f = 0.16

The ¹H-NMR, ¹³C-NMR, IR and MS spectra are consistent with the structure.

E) 2-[[[(3β,5β,7α,12α)-3-[(aminoacetyl)amino]-7,12-dihydroxy-24-oxocholan-24-yl]amino] ethanesulfonic acid sodium salt

90

22.4 g of compound D) (32.3 mmol) were suspended in 1M methanolic HCl (160 mmol, 160 ml) at room temperature. During the reaction time, the suspension became thicker and after 1 day the reaction mixture was filtered through a sintered glass filter. The collected solid was washed thoroughly with Et₂O/MeOH (1:1 v/v) and dried under reduced pressure obtaining the desired product (13.0 g; 20.6 mmol).

Yield: 64% m.p.: 200°C

HPLC: 94% (area %)

Stationary phase: Column E. Merck Lichrosorb Select B; 5 µm; 250 x 4 mm

Mobile phase: Gradient elution

A = aqueous solution 0.01 M in KH₂PO₄ and 0.017 M in H₃PO₄

B = CH₃CN

	min	% A	% B
	0	95	5
	30	20	80
	45	20	80

Flow rate: 1 ml min⁻¹

Temperature: 45 °C

Detector (UV): 210 nm

TLC: Silica gel plates 60 F₂₅₄ (E. Merck art. 5719)

Eluent: MeOH : AcOH = 95 : 5 (v/v)

Detection: AcOH : Conc. H₂SO₄ : p-anisaldehyde = 100 : 2 : 1 (v/v/v) R_f = 0.67

The ¹H-NMR, ¹³C-NMR, IR and MS spectra are consistent with the structure.

F) 10-[2-[[2-[(3β,5β,7α,12α)-7,12-dihydroxy-24-oxo-24-[(2-sulfoethyl)amino]cholan-3-yl]amino]-2-oxo-

ethyl]amino]-2-oxoethyl]-1,4,7,10-tetraazacyclodecane-1,4,7-triacetic acid

A solution of compound A) and triethylamine in DMF at 5°C was added drop by drop with isobutyl chloroformate and subsequently with a solution of compound B) in DMF. When the reaction was over solvent was evaporated under vacuum, the residue was dissolved with CH₂Cl₂ and trifluoroacetic acid was dropped therein at 0°C. When the addition was completed the mixture was left to react at room temperature. When the reaction was over the reaction mixture was evaporated under reduced pressure. The residue was taken up with CH₂Cl₂ and evaporated again repeating such a procedure 2 more times. The residue was purified and salted off by elution on an Amberlite R XAD-16 resin using a MeOH/H₂O gradient to obtain the desired product. The ¹H-NMR, ¹³C-NMR, IR and MS spectra are consistent with the structure.

G) Title compound

According to the procedure described in EXAMPLE 1, compound F) was reacted with GdCl₃.6H₂O in H₂O, maintaining at pH 6.5 by addition of 1N meglumine. The desired product was obtained that was salted off by elution with a MeOH/H₂O gradient on an Amberlyte XAD-16 resin.

The IR and MS spectra are consistent with the structure.

In the same way, the gadolinium complexes of the following ligands were prepared:

(3β,5β,7α,12α)-3-[[[[[4,7,10-tris(Carboxymethyl)-1,4,7,10-tetraazacyclododecyl]acetyl]amino]acetyl]ami-

no]-7,12-dihydroxy-cholan-24-oic acid (COMPOUND 31);
 N^2 -[(3 α ,5 β ,7 α ,12 α)-3,7,12-trihydroxy-24-oxocholan-24-yl]- N^6 -[[4,7,10-tris(carboxymethyl)-1,4,7,10-tetraazacyclododecyl]acetyl]-L-lysine (COMPOUND 32);

- 5 (3 β ,5 β ,7 α ,12 α)-3-[[6-[[[4,7,10-tris(carboxymethyl)-1,4,7,10-tetraazacyclododecyl]acetyl]amino]-1-oxohexyl]amino]-7,12-dihydroxy-cholan-24-oic acid (COMPOUND 33).

EXAMPLE 17

- 10 [[(3 α ,5 β ,7 α ,12 α)-3-[[3-[4,7,10-tris(carboxymethyl)-1,4,7,10-tetraazacyclododecyl]-2-hydroxypropyl]oxy]-7,12-dihydroxy-cholan-24-oate(4⁻)]gadolate(1⁻)] hydrogen compound with 1-deoxy-1-(methylamino)-D-glucitol (1:1)

- A) (3 α ,5 β ,7 α ,12 α)-3-(2,3-epoxypropyl)oxy-7,12-dihydroxy-cholan-24-oic acid 1,1-dimethylethyl ester

- 15 A mixture of 50% NaOH (10 ml), epichlorohydrin (6 ml) and tetrabutylammonium hydrogen sulfate (0.3 g) kept at 0°C was added drop by drop with a solution of (3 α ,5 β ,7 α ,12 α)-3,7,12-trihydroxy-cholan-24-oic acid
 20 1,1-dimethylethyl ester (prepared according to the procedure described by R. P. Bonar-Law et al., J. Chem. Soc. Perkin Trans. I, 1990, 2245) (0.0045 mol) in CH₂Cl₂ (10 ml). When the addition was completed the mixture was left to react at room temperature by 24 h.
 25 The organic phase was separated, washed with H₂O to neutral, dried over Na₂SO₄ and evaporated. The residue was purified by flash chromatography to obtain 0.86 g of desired product (0.0017 mol).

Yield: 37%

- 30 TLC: Carrier: silica gel plates 60 F₂₅₄ Merck
 Eluent: n-hexane : AcOEt = 1 : 1 (v/v)

Detector: AcOH : Conc. H_2SO_4 : p-anisaldehyde = 100:2:1

R_f = 0.3

The ^1H -NMR, ^{13}C -NMR, IR and MS spectra are consistent with the structure.

- 5 B) (3 α ,5 β ,7 α ,12 α)-3-[[3-[4,7,10-tris[2-(1,1-dimethylethoxy)-2-oxoethyl]-1,4,7,10-tetraazacyclododecyl]-2-hydroxypropyl]oxy]-7,12-dihydroxy-cholan-24-oic acid (1,1-dimethylethyl)ester

A solution containing compound A) (0.001 mol),
10 1,4,7,10-tetraazacyclododecane-1,4,7-triacetic acid tris(1,1-dimethylethyl)ester monohydrochloride (prepared according to Example 16) (0.001 mol) and triethylamine (1.5 ml) in EtOH (30 ml) was refluxed for 4 h. The reaction mixture was evaporated and the
15 residue was purified by flash chromatography to obtain 0.3 g of desired product (0.0003 mol).

Yield: 27%

TLC: Carrier: silica gel plates 60 F₂₅₄ Merck

Eluent: CH_2Cl_2 : MeOH = 9 : 1 (v/v)

20 Detector: AcOH : Conc. H_2SO_4 : p-anisaldehyde = 100:2:1

R_f = 0.34

The ^1H -NMR, ^{13}C -NMR, IR and MS spectra are consistent with the structure.

- 25 C) (3 α ,5 β ,7 α ,12 α)-3-[[3-[4,7,10-tris(carboxymethyl)-1,4,7,10-tetraazacyclododecyl]-2-hydroxypropyl]oxy]-7,12-dihydroxy-cholan-24-oic acid

A solution of compound B) in CH_2Cl_2 at 0°C was added drop by drop with trifluoroacetic acid. When the addition was completed the mixture was left to react at
30 room temperature. When the reaction was over the reaction mixture was evaporated under reduced pressure.

The residue was taken up with CH_2Cl_2 and evaporated again repeating such a procedure 2 more times. The residue was purified and salted off by elution on an Amberlite^R XAD-16 resin using a $\text{MeOH}/\text{H}_2\text{O}$ gradient to
5 obtain the desired product.

The ^1H -NMR, ^{13}C -NMR, IR and MS spectra are consistent with the structure.

D) Title compound

According to the procedure described in EXAMPLE 1,
10 compound C) was reacted with $\text{GdCl}_3 \cdot 6\text{H}_2\text{O}$ in H_2O , maintaining at pH 6.5 by addition of 1N meglumine. The resulting product was salted off by elution with a $\text{MeOH}/\text{H}_2\text{O}$ gradient on an Amberlite^R XAD-16 resin.

The IR and MS spectra are consistent with the
15 structure.

EXAMPLE 18

[[$(3\beta, 5\beta, 7\alpha, 12\alpha)$ -3-[[5-[4,7,10-tris(carboxymethyl)-
1,4,7,10-tetraazacyclododecyl]-4-hydroxy-1-oxopentyl]-
amino]-7,12-dihydroxy-cholan-24-oate(4^-)]gadolate-
20 (1^-)] hydrogen compound with 1-deoxy-1-(methylamino)-D-
glucitol (1:1)

A) $(3\beta, 5\beta, 7\alpha, 12\alpha)$ -3-(1-oxopent-4-enyl)amino-7,12-dihydroxy-cholan-24-oic acid methyl ester

A solution of 4-pentenoic acid (marketed product)
25 and triethylamine in THF was added drop by drop, under nitrogen and at 5°C , with isobutyl chloroformate and subsequently with a solution of $(3\beta, 5\beta, 7\alpha, 12\alpha)$ -3-amino-7,12-dihydroxy-cholan-24-oic acid methyl ester (prepared according to the procedure described in EXAMPLE 5)
30 in THF. When the reaction was over, solvent was evaporated and the residue was taken up with H_2O and

AcOEt. The organic phase was separated, washed with H₂O, dried over Na₂SO₄ and evaporated under reduced pressure. The residue was purified by flash chromatography to obtain the desired product.

5 The ¹H-NMR, ¹³C-NMR, IR and MS spectra are consistent with the structure.

B) (3β,5β,7α,12α)-3-(4,5-epoxy-1-oxopentyl)amino-7,12-dihydroxy-cholan-24-oic acid methyl ester

A solution of magnesium monoperphthalate in H₂O
10 was dropped into a solution of compound A) in CHCl₃ containing methyltriocetylammmonium chloride and kept at 50°C. The pH of the reaction mixture was maintained from 4.5 to 5 by addition of 5% NaOH. When the reaction was over the organic phase was separated and the
15 aqueous phase was extracted with CHCl₃. The organic phases were combined, washed with H₂O, dried over Na₂SO₄ and evaporated after checking for the absence of peroxides. The residue was purified by flash chromatography to obtain the desired product.

20 The ¹H-NMR, ¹³C-NMR, IR and MS spectra were consistent with the structure.

C) (3β,5β,7α,12α)-3-[[5-[4,7,10-tris[2-(1,1-dimethylethoxy)-2-oxoethyl]-1,4,7,10-tetraazacyclododecyl]-4-hydroxy-1-oxopentyl]amino]-7,12-dihydroxy-
25 cholan-24-oic acid

A solution containing B), 1,4,7,10-tetraazacyclododecane-1,4,7-triacetic acid tris(1,1-dimethylethyl)-ester monohydrochloride (prepared according to Example 16) and triethylamine in EtOH was refluxed for 4 h. The
30 reaction mixture was evaporated and the residue was purified by flash chromatography to obtain the desired

product.

The ^1H -NMR, ^{13}C -NMR, IR and MS spectra were consistent with the structure.

5 D) (3 β ,5 β ,7 α ,12 α)-3-[[5-[4,7,10-tris(carboxymethyl)-1,4,7,10-tetraazacyclododecyl]-4-hydroxy-1-oxopen-tyl]amino]-7,12-dihydroxy-cholan-24-oic acid

A solution of compound C) in CH_2Cl_2 at 0°C was added drop by drop with trifluoroacetic acid. When the addition was completed the mixture was left to react at
10 room temperature. When the reaction was over the reaction mixture was evaporated under reduced pressure. The residue was taken up with CH_2Cl_2 and evaporated again, repeating such a procedure 2 more times. The residue was purified and salted off by elution on an
15 Amberlite^R XAD-16 resin using a $\text{MeOH}/\text{H}_2\text{O}$ gradient to obtain the desired product.

The ^1H -NMR, ^{13}C -NMR, IR and MS spectra were consistent with the structure.

E) Title compound

20 According to the procedure described in EXAMPLE 1, compound D) was reacted with $\text{GdCl}_3 \cdot 6\text{H}_2\text{O}$ in H_2O , maintaining at pH 6.5 by addition of 1N meglumine. The resulting desired product was salted off by elution with a $\text{MeOH}/\text{H}_2\text{O}$ gradient on an Amberlyte XAD-16 resin.
25 The IR and MS spectra were consistent with the structure.

EXAMPLE 19

The relaxivities r_1 and r_2 ($\text{mM}^{-1} \cdot \text{s}^{-1}$) of the 4-carboxy-5,8,11-tris(carboxymethyl)-1-[4-[[[(3 α ,5 β ,7 α ,
30 12 α)-3,7,12-trihydroxy-24-oxocholan-24-yl]amino]acetyl]amino]phenyl]-2-oxa-5,8,11-triazatridecan-13-oic

acid gadolinium complex (Compound 1F) were evaluated in SERONORM-HUMANTM serum (NYCOMED), in a magnetic field of a 20 MHz frequency, at a temperature of 39°C, (MINISPEC PC-120 device), using the following sequences: Inversion Recovery; CPMG; and compared with those of Gd-DTPA/Dimeg (Magnevist^R), Gd-DOTA/meg (Dotarem^R), Gd-BOPTA/Dimeg and GdCl₃ [percent ratios being calculated with respect to GdCl₃] obtained under the same experimental conditions. The results are reported in Table 1.

Table 1

$$A = \frac{r_1(\text{Gd-compound})}{r_1(\text{GdCl}_3)}$$

$$B = \frac{r_2(\text{Gd-compound})}{r_2(\text{GdCl}_3)}$$

Compounds	r_1 (mM ⁻¹ .s ⁻¹)	A.100	r_2 (mM ⁻¹ .s ⁻¹)	B.100
Compound 1F	19.23	183.8	22.02	182.1
Compound 4F	12.02	114.9	13.74	113.6
Magnevist [®]	4.96	47.42	5.43	44.91
Dotarem [®]	4.34	41.49	5.02	41.52
Gd-BOPTA	9.31	89.00	11.19	92.55
GdCl ₃	10.46	100	12.09	100

CLAIMS

1. Compounds of general formula (I)



5 wherein

A is the residue of a bile acid, wherein by bile acid the group of the bile acids obtainable by bioconversion from cholesterol is meant, particularly the acids: cholic, deoxycholic,
10 chenodeoxycholic, ursodeoxycholic, lithocholic, and the derivatives thereof, including those with taurine and glycine;


L is a ligand between one of the C-3, C-7, C-12 or C-24 positions of the residue of the bile acid and
15 B, corresponding to a group of formula (II)



in which

20 m is an integer varying from 1 to 10, wherein for values above 1, Y can have different meanings,

Y corresponds to the following succession of groups,



n, l and q can be 0 or 1,

p can vary from 0 to 10,

X is an O atom, a S atom, or a -NR group,

30 in which

R is a H atom, or a (C₁-C₅) alkyl group,

99

K is benzene ring, substituted or not, or a $-\text{CHR}_1$ group,

wherein

R_1 is an hydrogen atom, or a $-\text{COOH}$ group, or a $-\text{SO}_3\text{H}$ group,

Z is an O atom or a S atom, or one of the $-\text{CO}-$ or $-\text{CS}-$ groups,

B is the residue of a chelating agent of the bi-trivalent metal ions having an atomic number varying from 20 to 31, 39, 42, 43, 44, 49, or from 57 to 83, wherein said residue can in its turn be conjugated or not, by a second chain L of formula (II), to another residue A as defined above,

with the proviso that at least one from l, n, q, p is different from 0 and in case X and Z are both O or S atoms, q or n is equal to 1,

as well as complex chelates of said compounds of formula (I) with ions of metal elements having atomic number ranging from 20 to 31, 39, from 42 to 44, 49 and from 57 to 83 and the salts thereof with physiologically acceptable organic bases selected from primary, secondary, tertiary amines or basic amino acids, or with inorganic bases whose cations are sodium, potassium, magnesium, calcium or mixtures thereof, or with physiologically acceptable anions of organic acids selected from acetate, succinate, citrate, fumarate, maleate, oxalate, or with anions of inorganic acids selected from halohydric acid ions.


2. Compounds according to claim 1, wherein A is selected from one of the following bile acids: cholic, deoxycholic, chenodeoxycholic, ursodeoxycholic, lito-

100

cholic and derivatives thereof, including those conjugated with taurine and glycine.

3. Compounds according to claim 1, wherein B is selected from the following polyaminocarboxylic acids and ester or amide derivatives thereof: EDTA; DTPA; EOB-DTPA; BOPTA; DTPA-BMA; DOTA; DOTMA; DO3A; HPDO3A; MCTA; or B is selected from the following acids: DPDP; EDTP; or B is selected from the following polyaminophosphonic acids and derivatives thereof or polyaminophosphinic acids and derivatives thereof: 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetrakis[methylene(methylphosphinic)] acid and 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetrakis[methylene(methylphosphonic)] acid; or B is selected from macrocyclic chelants selected from texafirines, porphyrins and phthalocyanines.

4. Compounds according to claim 1, wherein the spacing chain L has the following general formula (III),




wherein R, R₁, l, m, n, p and q are as defined above.

5. Compounds according to claim 1, wherein the spacing chain L has the following general formula (IV),


30

101




10 wherein R, R₁, l, m, n, p and q are as defined above.

6. Compounds according to claim 1, wherein the spacing chain L has the following general formula (V),



wherein R, R₁, l, m, n, p and q are as defined above.

7. Compounds according to claim 1, wherein the spacing chain L has the following general formula (VI),



wherein R, l, m, n, p and q are as defined above.

8. Compounds according to claim 1, wherein bi- or trivalent metal ion complexed by the chelant residue B is selected from $\text{Fe}(2^+)$, $\text{Fe}(3^+)$, $\text{Gd}(3^+)$, $\text{Eu}(3^+)$,
5 $\text{Dy}(3^+)$, $\text{La}(3^+)$, $\text{Yb}(3^+)$ and $\text{Mn}(2^+)$, or is a radioisotope selected from ^{51}Cr , ^{67}Ga , ^{68}Ga , ^{111}In , $^{99\text{m}}\text{Tc}$, ^{140}La , ^{175}Yb , ^{153}Sm , ^{166}Ho , ^{90}Y , ^{149}Pm , ^{177}Lu , ^{47}Sc , ^{142}Pr , ^{159}Gd , ^{212}Bi .

9. Compounds according to claim 1, wherein the
10 physiologically acceptable salifying organic base is selected from ethanolamine, diethanolamine, morpholine, glucamine, N,N-dimethylglucamine, N-methylglucamine, lysine, arginine, ornithine.

10. Compounds according to claim 1, wherein
15 physiologically acceptable salifying inorganic acid anion is a halohydric acid ion selected from chlorides, bromides and iodides.

11. Compounds according to claim 1 wherein A is a residue of cholic acid or of a derivative thereof and B
20 is a residue of DTPA or of a derivative thereof.

12. Compounds according to claim 1 wherein A is a residue of cholic acid or of a derivative thereof and B is a residue of BOPTA or of a derivative thereof.

13. Compounds according to claim 1 wherein A is a
25 residue of cholic acid or of a derivative thereof and B is a residue of DOTA or of a derivative thereof.

14. A compound according to claims 1 to 13, wherein the derivative of formula (I) is selected from the following:

30 Comp. 1 $[[[4\text{-carboxy-5,8,11-tris(carboxymethyl)-1-[4-} \\ [3,7,12\text{-trihydroxy-24-oxo-}$

- cholan-24-yl]amino]acetyl]amino]phenyl]-2-oxa-5,8,11-triazatridecan-13-oic acid;
- Comp. 2 [[4-carboxy-5,8,11-tris(carboxymethyl)-1-[4-
5 [[(3 α ,5 β ,7 α ,12 α)-3,7,12-trihydroxy-24-oxo-
cholan-24-yl]amino]phenyl]-2-oxa-5,8,11-tria-
zatridercan-13-oic acid;
- Comp. 3 [[3,6,9-tris(carboxymethyl)-10-(phenylmetho-
xy)methyl-11-oxo-14-[[[(3 α ,5 β ,7 α ,12 α)-3,7,12-
trihydroxy-24-oxocholan-24-yl]amino]-3,6,9,-
10 12-tetraazatetradecanoic acid;
- Comp. 4 [[10-[2-oxo-2-[[3-[[2-[[[(3 α ,5 β ,7 α ,12 α)-3,7,-
12-trihydroxy-24-oxocholan-24-yl]amino]-
ethyl]amino]propyl]amino]ethyl]-1,4,7,10-
tetraazacyclododecan-1,4,7-triacetic acid;
- 15 Comp. 5 [[(3 β ,5 β ,7 α ,12 α)-3-[[13-carboxy-6,9,12-tris-
(carboxymethyl)-1,4-dioxo-5-[(phenylmethoxy)-
methyl]-3,6,9,12-tetraazatridecyl]amino]-7,-
12-dihydroxy-cholan-24-oic acid;
- Comp. 6 [[(3 β ,5 β ,7 α ,12 α)-3-[[17-carboxy-10,13,16-
20 tris(carboxymethyl)-8-oxo-9-[(phenylmetho-
xy)methyl]-3,7,10,13,16-pentaazaheptadecyl]-
oxy]-7,12-dihydroxy-cholan-24-oic acid;
- Comp. 7 [[[(3 β ,5 β ,7 α ,12 α)-7,12-dihydroxy-3-[2-[[[4-
[4,12-bis(carboxy)-5,8,11-tris(carboxyme-
25 thyl)-2-oxa-5,8,11-triazadodecyl]phenyl]ami-
no]thioxomethyl]amino]ethoxy]-cholan-24-oic
acid;
- Comp. 8 (3 β ,5 β ,7 α ,12 α)-7,12-dihydroxy-3-[[[3-[[[4,-
7,10-tris(carboxymethyl)-1,4,7,10-tetraazacy-
30 clodec-1-yl]acetyl]amino]propyl]amino]ace-
tyl]amino]-cholan-24-oic acid;

- Comp. 9 [[3,6,9-tris(carboxymethyl)-10-[(phenylmethoxy)methyl]-11-oxo-17-[[[(3 α ,5 β ,7 α ,12 α)-3,7,12-trihydroxy-24-oxocholan-24-yl]amino]-3,6,9,12-tetraazaoctadecanedioic acid;
- 5 Comp. 10 [[[(3 β ,5 β ,7 α ,12 α)-3-[[13-carboxy-6,9,12-tris(carboxymethyl)-1,4-dioxo-3,6,9,12-tetraazatridecyl]amino]-7,12-dihydroxy-cholan-24-oic acid;
- 10 Comp. 11 [(3 β ,5 β ,7 α ,12 α)-(3' β ,5' β ,7' α ,12' α)-3,3'-[[6,9,12-tris(carboxymethyl)-1,4,14,17-tetraoxo-3,6,9,12,15-pentaazaheptadecan-1,17-diyl]bisimino]bis[7,12-dihydroxycholan-24-oic acid;
- 15 Comp. 12 [[[(3 β (S),5 β ,7 α ,12 α)-7,12-dihydroxy-3-[[4-[[[5-[bis[2-[bis(carboxymethyl)amino]ethyl]amino]-5-carboxypentyl]amino]thioxomethyl]amino]benzoyl]amino]-cholan-24-oic acid;
- 20 Comp. 13 [[[(3 β (S),5 β ,7 α ,12 α)-7,12-dihydroxy-3-[[4-[[5-[bis[2-[bis(carboxymethyl)amino]ethyl]amino]-5-carboxypentyl]amino]-1,4-dioxobutyl]amino]-cholan-24-oic acid;
- 25 Comp. 14 [[[(3 β ,5 β ,7 α ,12 α)-7,12-dihydroxy-3-[[4-[[2-[[4-[4,12-bis(carboxy)-5,8,11-tris(carboxymethyl)-2-oxa-5,8,11-triazadodecyl]phenyl]amino]-2-oxoethyl]amino]-1,4-dioxobutyl]amino]-cholan-24-oic acid;
- 30 Comp. 15 3,6,9-tris(carboxymethyl)-14-[[[(3 β ,5 β ,7 α ,12 α)-7,12-dihydroxy-24-oxo-24-[(2-sulfoethyl)amino]-cholan-3-yl]amino]-11,14-dioxo-3,6,9,12-tetraazatetradecanoic acid;
- Comp. 16 N-[(3 β ,5 β ,7 α ,12 α)-3-[[13-carboxy-6,9,12-tris(carboxymethyl)-1,4-dioxo-5-[(phenylmethoxy)-

105

- methyl]-3,6,9,12-tetraazatridecyl]amino]-7,-
12-dihydroxy-24-oxocholan-24-yl]glycine
- Comp. 17 (3 β ,5 β ,7 α)-3-[[13-carboxy-6,9,12-tris(carboxymethyl)-1,4-dioxo-5-[(phenylmethoxy)methyl]-3,6,9,12-tetraazatridecyl]amino]-7-hydroxy-cholan-24-oic acid;
- 5
- Comp. 18 (3 β ,5 β ,12 α)-3-[[13-carboxy-6,9,12-tris(carboxymethyl)-1,4-dioxo-5-[(phenylmethoxy)methyl]-3,6,9,12-tetraazatridecyl]amino]-12-hydroxy-cholan-24-oic acid;
- 10
- Comp. 19 (3 β ,5 β)-3-[[13-carboxy-6,9,12-tris(carboxymethyl)-1,4-dioxo-5-[(phenylmethoxy)methyl]-3,6,9,12-tetraazatridecyl]amino]-cholan-24-oic acid;
- 15
- Comp. 20 (3 β ,5 β ,7 α ,12 α)-3-[[17-carboxy-10,13,16-tris(carboxymethyl)-1,8-dioxo-9-[(phenylmethoxy)methyl]-7,10,13,16-tetraazaheptadecyl]amino]-7,12-dihydroxy-cholan-24-oic acid;
- Comp. 21 (3 β ,5 β ,7 α ,12 α)-7,12-dihydroxy-3-[[3-[[[4,-
- 20
- 7,10-tris(carboxymethyl)-1,4,7,10-tetraazacyclododec-1-yl]acetyl]amino]propyl]amino]-cholan-24-oic acid;
- Comp. 22 3,6,9-tris(carboxymethyl)-14-[[3,5 β ,7 α ,12 α)-7,12-dihydroxy-24-oxo-24-[(2-sulfoethyl)amino]-cholan-3-yl]amino]-11,14-dioxo-
- 25
- 3,6,9,12-tetraazatetradecanoic acid;
- Comp. 23 [(3 β ,5 β ,7 α ,12 α)-3-[[17-carboxy-10,13,16-tris(carboxymethyl)-1,8-dioxo-7,10,13,16-tetraazaheptadecyl]amino]-7,12-dihydroxy-cholan-
- 30
- 24-oic acid;
- Comp. 24 (17S)-3,6,9-tris(carboxymethyl)-11-oxo-17-

106

- [[(3 β , 5 β , 7 α , 12 α)-3, 7, 12-trihydroxy-24-oxocholan-24-yl]amino]-3, 6, 9, 12-tetraazaoctadecanedioic acid;
- 5 Comp. 25 [[(3 β , 5 β , 7 α , 12 α)-3-[[6-[[[bis[2-[bis(carboxymethyl)amino]ethyl]amino]acetyl]amino]-1-oxohexyl]amino]-7, 12-dihydroxy-cholan-24-oic acid;
- 10 Comp. 26 (3 β , 5 β , 7 α , 12 α)-3-[[[[[bis[2-[bis(carboxymethyl)amino]ethyl]amino]acetyl]amino]acetyl]-amino]-7, 12-dihydroxy-cholan-24-oic acid;
- Comp. 27 N⁶-[[bis[2-[bis(carboxymethyl)amino]ethyl]-amino]acetyl]-N²-[(3 α , 5 β , 7 α , 12 α)-3, 7, 12-trihydroxy-24-oxocholan-24-yl]-L-lysine
- 15 Comp. 28 [[N⁶-[(4S)[4-[bis[2-[bis(carboxymethyl)amino]ethyl]amino]-4-carboxy]-1-oxobutyl]-N²-[(3 α , 5 β , 7 α , 12 α)-3, 7, 12-trihydroxy-24-oxocholan-24-yl]-L-lysine
- 20 Comp. 29 [3 β (S), 5 β , 7 α , 12 α]-3-[4-carboxy-4-[bis[2-[bis(carboxymethyl)amino]ethyl]amino]-1-oxobutyl]amino]-7, 12-dihydroxy-cholan-24-oic acid;
- 25 Comp. 30 [[10-[2-[[2-[[(3 β , 5 β , 7 α , 12 α)-7, 12-dihydroxy-24-oxo-24-[(2-sulfoethyl)amino]cholan-3-yl]-amino]-2-oxoethyl]amino]-2-oxoethyl]-1, 4, -7, 10-tetraazacyclododecane-1, 4, 7-triacetic acid;
- Comp. 31 (3 β , 5 β , 7 α , 12 α)-3-[[[[[4, 7, 10-tris(carboxymethyl)-1, 4, 7, 10-tetraazacyclododecyl]acetyl]-amino]acetyl]amino]-7, 12-dihydroxy-cholan-24-oic acid;
- 30 Comp. 32 N²-[(3 α , 5 β , 7 α , 12 α)-3, 7, 12-trihydroxy-24-oxocholan-24-yl]-N⁶-[[4, 7, 10-tris(carboxyme-

107

thyl)-1,4,7,10-tetraazacyclododecyl]acetyl]-
L-lysine

Comp. 33 (3 β ,5 β ,7 α ,12 α)-3-[[6-[[[4,7,10-tris(carboxy-
methyl)-1,4,7,10-tetraazacyclododecyl]ace-
tyl]amino]-1-oxohexyl]amino]-7,12-dihydroxy-
cholan-24-oic acid;

Comp. 34 [[(3 α ,5 β ,7 α ,12 α)-3-[[3-[4,7,10-tris(carboxy-
methyl)-1,4,7,10-tetraazacyclododecyl]-2-hy-
droxypropyl]oxy]-7,12-dihydroxy-cholan-24-oic
acid;

Comp. 35 [[(3 β ,5 β ,7 α ,12 α)-3-[[5-[4,7,10-tris(carboxy-
methyl)-1,4,7,10-tetraazacyclododecyl]-4-hy-
droxy-1-oxopentyl]amino]-7,12-dihydroxy-cho-
lan-24-oic acid.

15 15. Contrast diagnostic pharmaceutical compositions
comprising at least one of the complex chelates
according to claims 1 to 14 or a salt thereof.

16. Pharmaceutical composition according to claim 15,
to obtain images of organs and/or tissues of human and
20 animal body, through the use of nuclear magnetic
resonance.

17. The use of the complex chelates of the compounds
of formula (I) or of the salts thereof for the
preparation of diagnostic formulations to obtain images
25 of organs and/or tissues of human and animal body,
through the use of nuclear magnetic resonance.

18. The use of the complex chelates of the compounds
of formula (I) or of the salts thereof for the
preparation of diagnostic formulations to obtain images
30 of the hepatobiliary system of human and animal body,
through the use of nuclear magnetic resonance.

INTERNATIONAL SEARCH REPORT

Intern. Application No

PCT/EP 95/01958

A. CLASSIFICATION OF SUBJECT MATTER
IPC 6 A61K49/00 A61K51/04

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	EP-A-0 417 725 (HOECHST AG.) 20 March 1991 cited in the application see claims see page 3 - page 11 ---	1
X	EP-A-0 279 307 (ABBOTT LABORATORIES) 20 March 1991 cited in the application see page 4, line 40 - page 7, line 24 see page 14, line 12 - line 26; claims see page 12 see page 13, line 48 - line 57 ---	1-18
A	US-A-5 169 944 (NELSON JAMES A ET AL) 8 December 1992 see column 5, line 52 - line 61; claims --- -/--	1-3, 15-18

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents :

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

- *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- *&* document member of the same patent family

Date of the actual completion of the international search

15 September 1995

Date of mailing of the international search report

26.09.95

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Berte, M

INTERNATIONAL SEARCH REPORT

International Application No
PCT/EP 95/01958

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	<p>BIOCONJUGATE CHEM. (1991), 2(2), 117-23 CODEN: BCCHE;ISSN: 1043-1802, 1991</p> <p>BETEBENNER, DAVID A. ET AL 'Hepatobiliary delivery of polyaminopolycarboxylate chelates: synthesis and characterization of a cholic acid conjugate of EDTA and biodistribution and imaging studies with its indium-111 chelate' see page 119; figure 1 ---</p>	1-5,7,8, 10,14,15
A	<p>J. AM. CHEM. SOC. (1989), 111(8), 2900-9 CODEN: JACSAT;ISSN: 0002-7863, 1989</p> <p>GROVES, JOHN T. ET AL 'Regioselective oxidation catalysis in synthetic phospholipid vesicles. Membrane-spanning steroidal metalloporphyrins' see figures 1,2; table 1 ---</p>	1-5,7,8
E	<p>WO,A,95 19186 (NYCOMED IMAGING A S ;MATTHEWS DEREK PETER (GB); KLAVERNESS JO (NO);) 20 July 1995 see page 5, paragraph 2 see page 7, paragraph 4 - page 9, paragraph 3; claims -----</p>	1-18

INTERNATIONAL SEARCH REPORT

Information on patent family members

Intern. Application No

PCT/EP 95/01958

Patent document cited in search report	Publication date	Patent family member(s)	Publication date	
EP-A-417725	20-03-91	DE-A-	3930696	28-03-91
		AU-B-	637822	10-06-93
		AU-A-	6244190	21-03-91
		CA-A-	2025294	15-03-91
		IL-A-	95668	30-03-95
		JP-A-	3109396	09-05-91

EP-A-279307	24-08-88	US-A-	5057302	15-10-91
		AU-B-	605241	10-01-91
		AU-B-	1168588	18-08-88
		DE-D-	3884233	28-10-93
		DE-T-	3884233	03-03-94
		ES-T-	2059411	16-11-94
		JP-A-	63290854	28-11-88
		US-A-	5227474	13-07-93

US-A-5169944	08-12-92	NONE		

WO-A-9519186	20-07-95	NONE		
